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ABSTRACT 
Interaction of beta -cyclodextrin with ampicillin, phenobarbitone , 
and phenytoin was studied and complexation was observed with all three 
drugs . Analytical methods for the quantification of these drugs were 
validated. In order to obtain an inclusion compound in the solid 
powdered form, a variety of methods (freeze drying, spray drying, 
kneading, and solvent evaporation) was evaluated. Among these methods 
freeze dryi ng was the most feasible and reproducible method from a 
laboratory scale to a pilot scale and to the manufacturing level. 
Methods using an industrial model freeze drier were developed which 
resulted in an increase in yield from 53% to more than 90% . However, 
because of ampicillin instability in freezing conditions, it was not 
possible to obtain an inclusion compound in the solid powdered form . 
Physico-chemical properties of the inclusion complexes were 
evaluated by a variety of methods such as stability, solubility, X-ray 
diffractometry, differential scanning calorimetry, infrared and proton 
magnetic resonance spectroscopies, photomicrographs, etc. The stability 
of ampicillin in an acidic medium (pH 2.0) was considerably improved by 
complex formation with beta-cyclodextrin. The observed apparent 
pseudo-first order rate constants (hr- 1) of ampicillin were 1.8 x 10- 2, 
1. 2 x 10-2, and 1.1 x 10-2 for ratios of .1:0.0 and 1:1 . 0, 1:0.0 and 1:1 . 5 
and 1:0.0 and 2.0 of ampicillin to beta-cyclodextrin, respectively. 
Furthermore, it was estimated that the complex degrades nine times slower 
than the drug itself, and the apparent stability constant was found to be 
458.46M- 1. Aqueous solubility of phenobarbitone and phenytoin 
beta-cyclodextrin complexes were five and eleven fold larger than that 
of phenobarbitone and phenytoin alone, respectively. A phase solubility 
diagram was constructed and the apparent stability constants were 
calculated for phenobarbitone and phenytoin beta-cyclodextrin complexes. 
The calculated stability constants were 4.54 X 103M-l and 766M- l for 
phenobarbitone and phenytoin complexes respectively. Thus, the formation 
and presence of the inclusion complex were confirmed by stability and 
solubility analysis. Furthermore, the proton magnetic resonance spectra 
of phenobarbitone beta-cyclodextrin complex strongly indicated the 
presence of the inclusion complex in the liquid phase. The mode of 
interaction and elucidation of the presence of the inclusion complex in 
the solid phase were studied by X-ray diffraction, differential scanning 
calorimetry, infrared spectra photomicrographs, etc . The X-ray 
diffraction spectra and differential scanning calorimetry thermograms 
clearly suggested the presence of the inclusion complex in the freeze 
dried material but not in the physical mixture. The infrared spectra and 
photomicrographs evaluations were such that a definitive, unambiguous 
interpretation could not be made; however, they were useful to some 
extent to show the interaction with beta -cyclodextrin. 
A solution was prepared from the phenobarbitone beta-cyclodextrin 
complex. Unlike an official USP preparation, the solution prepared from 
the complex did not require the addition of alcohol to keep the 
phenobarbitone in solution. Four months' physical and one month's 
chemical stability data indicated a considerable potential especially for 
pediatric use. It was possible to prepare a pharmaceutically elegant 
suspension from the phenytoin beta-cyclodextrin complex. The suspensi on 
possessed desirable qualities of a pharmaceutically elegant suspension, 
such as ease of dispersion, high sedimentation volume, etc.; in addition, 
the ~uspension had a low viscosity. Physical stability was good even in 
freezing conditions and a syr ingeability study suggested a potential for 
intramuscular use. 
A flow study was designed using a recording flowmeter with small 
quantities of material in an attempt to predict the flow rate during 
large scale operations . The data indicated that the flowmeter was 
sensitive enough that a small quantity of material could be used to 
predict the flow rate, effect of formulation and processing variables on 
production scale quantities. The flow study, and the bulk properties of 
beta-cyclodextrin suggested that the material was fairly free flowing and 
compressible. The fre eze dried phenytoin beta-cyclodextrin complex 
lacked flowability and compressibility; neverthless, it was possible to 
compress tablets of a suitable size and weight using the wet granulation 
method. All the properties of tablets were measured and found to be 
within the USP standards. Dissolution studies in different test media 
strongly suggested that the dissolution rate. for phenytoin 
beta-cyclodextrin complex tablets was superior to all other phenytoin 
formulations or preparations. Furthermore, due to in situ complexation 
in the dissolution medium, the dissolutio n rate of the physical mixture 
of the freeze dried phenytoin and beta-cyclodextrin was found to be 
similar to the dissolution rate of the freeze dried complex. 
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PLAN OF THE THESIS 
This manuscript is divided into seven sections, numbered in Roma n 
numerals. The sections are: I. Introduction, II. Experimental, III. 
Results and Discussion, IV . Conclusions and Suggestions for future work, 
V. References, VI. Bibliography, VII. Appendix. The tables and 
figueres are numbered in Roman and Arabic numerals respectively . 
In this thesis the tenn " Inclusion complex, or Inclusion compound 
is often used. The meaning of the tenn is defined on page # 10 . The 
Results and Discussion are organized into the following main sections: A. 
Physico-chemical properties of complexes, B. Preparation of the 
complexes, C. Preparation and evaluation of dosage fonns . 
In some cases, the figures in this manuscript depict a horizonta l 
dotted line. It represents the calculated percent drug dissolved based 
on the equil i brium solubility. When experimental points are joined by 
lines on figures, no mathematical relationships are implied . All the 
error bars represent standard deviation unless otherwise marked 
differently in the key to the figure. 
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I INTRODUCTION 
A- -Historical background 
The first reference to cyclodextrin was made in a publication of 
"Villers in 1891 (1), who isolated a small amount of a crystalline 
substance from a culture of Bacillus amylobacter, grown on a medium 
containing starch. Villers named his crystalline product " Cellulosine " 
because of its similarity to cellulose. Then Schardinger (2 -4 ) observed 
that Villers cellulosine often formed on starch-based culture media as a 
product of putrefying microorganisms. Schardinger succeeded in isolating 
a bacillus which he named Bac illus macerans . This is the most frequently 
used source of the enzyme glycosyl-transferase by which cyclodextrin is 
now produced. 
Afte r Schardinger, it was Pringsheim (5) who played the major role 
in the cyclodextrin research, and he discovered the complexing power of 
the cyclodextrins. From the mid - thirties on, pure cyclodextrins were 
prepared, first by Freudenberg and his co -workers, who also elucidated 
the chemical structure of cyclodextrins and discovered gamma -cyclodextrin 
(6) . The cyclodextrins, also called cycloamyloses, Schardinger dextrins, 
or Cycloglycopyranoses, are cyclic oligosaccharides in which glucose 
units are linked by alpha 1-4 glycosidic bonds (7,8). French (7) in the 
mid-fifties demonstrated the existence of delta and epsilon 
cyclodextrins. Thoma and Stewart (9) described further homologues 
containing 11 and 12 glycopyranose units. 
2 
8-Properties of cyclodextrins 
1. Physico-chemical properties 
Since the discovery of the Schardinger dextrins, these cyclic 
compounds have been of special interest as they relate to starch (7) . 
However, with respect to various chemical reactions, especially their 
biochemical behavior, the Schardinger dextrins vary from starch in 
important aspects (7,10). One of the rather remarkable properties of the 
Schardinger dextrins is their resistance to hydrolysis by the common 
starch- splitting enzymes; for example, it has been repeatedly reported 
that the Schardinger dextrins are resistant to beta amylase action. 
Since the Schardinger dextrins, are cyclic, there are no reducing end 
groups; hence they are resistant to beta amylase attack . The Schardinger 
dextrins have been reported (11) to be stable to alpha type amylases. 
Three types of cyclodextrins are most common: (a) Alpha -cyclodextrin 
containing six glucose units arranged in a ring and called 
alpha-Schardinger dextrin or cyclohexaamylose. (b) Beta-cycl odextrin 
containing seven glucose units and named beta-Schardinger dextrin or 
cycloheptaamylose. (c) Gamma-cyclodextrin containing eight glucose units 
and named gamma - Schardinger dextrin or cyclooctaamylose. The structure 
and molecular dimensions of these cyclodextrins are shown in Figs . l and 
2., and some of their more important physico-chemical properties are 
given in Table I (8,12). 
French and co-workers (13) found that the alpha-dextrin is 
essentially completely resistant to beta amylase, the beta-dextrin is 
attacked very slowly indeed and gamma-dextrin is attacked about l % as 
rapidly as is starch. So it is clear that the ring size exerts an 
effect; possibly the smaller rings have greater rigidity and hence can 
3 
Fig . 1 Struccures of Alpha, Beta , and Gamma Cyclodextrins. 
(Taken from Ref. 8). 
Alpha 
Gamma 
~ I
c::::::) 
.... 
············ ·· 
4 
Bei:a 
Fig . 2 Dimensions of Alpha, Beta, and Gamma Cyclodextrins. 
(Taken from Ref. 23). 
5 
Table I 
Some physico-chemical properties of .cyclodextrins 
Alpha Beta Gamma 
~----------- ~ - - - --- -
Molecular weight 972 1135 1297 
Diameter of cavity 4.5-6.0A0 8.0A0 lOAo 
Volume of cavity l 76A 03 346A03 510A03 
Number of water molecules 
taken up by cavity 6 11 17 
Molecules per unit cell 4 2 6 
Solubility in water gm./lOOml. 
at 25°c. 14.5 1.85 23.2 
6 
not adapt their shape to that required by the enzyme. Researchers are 
still left with the enigma as to why ring closure exerts such a profound 
effect on the starch chain. In particular, interest has been focused on 
the question as to which part of the starch structure gives rise to the 
cyclic .molecules. The cyclodextrins are not sensitive to alkalies, and 
they have no well defined melting points: from 300°c on they start to 
decompose. The density of cyclodextrins is l.42-l.45g/cm- 3, solubility 
data, molecular weight, cavity diameter, etc. are given in Table I. The 
cyclodextrins are white crystalline powders, very stable, slightly sweet 
in taste, and they are more resistant to hydrolysis than the linear 
dextrins (8). There are no reported data available in the literature 
with respect to flow and compression characteristics of cyclodextrins 
(Some of these properties are the subject of this study). 
In solution, the cyclodextrin's cavity cannot be regarded as an 
empty space. For example, the diameter of the cavity in 
alpha-cyclodextrin is 4.5A0 and its height is 6.7A0 and therefore the 
total volume is 64ml/mole. The energy required to maintain an empty 
space of this dimension would be approximately 40kcal/mole. This value 
is so high that it is hardly conceivable that the cavity could remain 
empty (8). The other two cyclodextrins (beta and gamma), having a larger 
diameter, this 'energy requirement is even higher. The viscosity of 
aqueous cyclodextrin solutions differs only insignificantly from that of 
water (14). One of the most striking properties of cyclodextrins is 
their ability to form inclusion complexes (8,15). This property will be 
dicussed in detail separately. 
2. Cyclodextrin metabolism and toxicity 
Detailed studies of metabolism and toxicity are necessary for any 
compound intended for use in pharmaceuticals or in food. Therefore, 
utilization of the cyclodextrins in the pharmaceutical or food industries 
depends to a large extent on knowledge of the effects they have on living 
organisms. In 1963 it was discovered that, in rats, 14C - labeled alpha 
and beta cyclodextrins are distributed into tissues and organs similarly 
to 14C-labeled starch (10) . It is remarkable that, on feeding 
14C-starch, the 14C-level of the 14C02 expired reached a maximum after 
one hour; whereas, in the case of 14C-beta cyclodextrin, the maximum 
appeared after approximately nine- hours. The total quantity of expired 
14C02 when related to the carbbohydrate consumed, was about equal in both 
experients. The cyclodextrins are not metabolized as rapidly as starch; 
this is because they are cleaved more slowly than linear dextrins (10), 
and are not hydrolyzed by enzymes which attack terminal groups. 
Szejtli et al. (16), reported a study in which they fed rats with 
beta-cyclodextrin and glucose, both uniformly labeled with 14C, and 
measured the radioactivity level of blood and exhaled air. With glucose, 
about 2 % of the initial radioactivity was found to be present in blood 
within 10-min. With labeled beta-cyclodextrin, only 0.5 % of the initial 
radioactivity could be recovered from blood and this value was reached 
only between the 4th and 10th hour following administration . The amount 
of exhaled radioactivity was practically identical with rats treated 
orally with 14C -glucose or 14C~beta cyclodextrin and followed for a 24- hr 
period. No significant difference was found in the tissue distribution 
of radioactivity (17 ) . Further studies (15,16) indicated that beta 
cyclodextrin is metabolized and that the intestinal flora are probably 
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responsible for the first step in the degradation of cyclodextrin. 
Attempts to detect the intact beta-cyclodextrin by high performance 
liquid chromatography) in blood following oral administration of 
14C-labeled substance gave negative results; no significant radioactivity 
was found at retention times that correspond to the beta-cyclodextrin. 
Chronic six months oral toxicity of the beta-cyclodextrin was 
studied with doses up to l.6gm./body weight kg. / day in rats, and up to 
0.6gm . /body weight kg./day in dogs (18). No toxic effects were observed 
with respect to weight gain, food consumption, or biochemical values of 
clinical significance. Pathologic and histopathologic investigations 
following the six-month treatment did not reveal any sign of toxicity in 
the digestive organs, central nervous system, cardiovascular system, or 
in any other organ tested. In addition, the beta-cyclodextrin was also 
devoid of embryotoxic effect. Chromosomal tests performed in rats 
treated for six months did not reveal increased incidence of spontaneous 
abberrations or gene mutation (18). The cyclodextrins administered in 
high doses (above SOmg./body weight kg . ) subcutaneously, 
intraperitoneally, or intravenously, can induce renal damage in the rat, 
but at lower doses the compound can be administered without ill effects 
( 20,21). 
All toxicity tests have shown that the orally administered 
cyclodextrin is innocuous. According to the report (22) of the ·Food and 
Agriculture Organization (FAD), enzjmatically modified starch-- this 
includes cyclodextrins-- is also · toxicologically harmless. The FAQ 
report concludes that there is no need to conduct a toxicological 
examination in the case of enzjlllatically modified starch products. 
However, considering the reduced activity of starch-degrading enzjmes 
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towards cyclodextrins, and also their retarded resorption and slow 
metabolism when administered orally, it is the author's opinion that 
additional toxicological studies of cyclodextrins seem nevertheless to be 
justified, especially if the parenteral route of administration were to 
be used. 
3. Cyclodextrin derivatives 
Among the natural cyclodextrins, beta-cyclodextrin is widely used in 
many fields because of its cavity size (8 .0 A0 }, and the ease with which 
it can be obtained at a relatively low cost on a large scale (8,15,23) . 
The present cost of this material is about $ 500 per kilogram. Numerous 
derivatives of cyclodextrins have already been reported (8) . However, 
for biomedical applications only a small number of cyclodextrin 
derivatives have been tested (24). 
Recently, the chemically modified cyclodextrins have received 
considerable attention because their physico-chemical properties are 
different from those of the natural cyclodextrins (25) . Among the 
properties that can be modified are solubility, membrane permeability, 
chemical reactivity, and dissociation constant (26). These properties 
will provide a rational basis for the design of formulations, and a means 
of improving the efficiency of drug activity; however, it should also be 
noted that modified cyclodextrins cause more hemolysis and local tissue 
damage than do natural cyclodextrins (27) . Hence, the practical 
application of modified cyclodextrins must await the results of 
exhaustive toxicological studies. 
C-lnclusion complexes 
For a half century chemists speculated that certain molecular 
structures might enclose other structures of suitable size and geometry. 
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It was not until late 1940's that this fonn of molecular architecture was 
actually shown to exist. Then, as so often happens, when the time is 
ripe, the discovery was made almost simultaneously by several research 
groups (15,28-33). The tenn " Einschlussverbindung " (i nclusion 
compound) was introduced by Schlenk (33) . Schlenk defines inclusion 
compounds as addition compounds in which one entity fits into and is 
surrounded by the crystal lattice of the other. These inclusion 
compounds may be called" no bond" complexes and are characterized by 
the lack of adhesive forces between the components of the complex. It is 
not a chemical interaction which is the primary force which causes an 
inclusion compound to fonn, although this may be a factor in the net 
complexation observed . There are some other names for inclusion 
compounds used in the literature, such as, abduct, clathrate, molecular 
compound, complex, etc. Inclusion complexes are known in six different 
fonns (34), depending on the architecture of the " host " structures and 
the shapes of the cavities they enclose (Fig. 3) . The structural 
arrangements that allow this snug 11 hand in glove 11 or 11 lock and key" 
fitting of molecular shapes differ from one family of inclusion compounds 
to another (34). In any event, according to John F. Brown Jr . (34), the 
discovery and detaiJed understanding of inclusion compounds have provided 
a powerful support for the hypothesis that such " hand in glove " or 
" lock and key 11 structures ca n indeed account for biochemical 
specificity, and hence that inclusion structures play a central role in 
the functioning of living orga nisms. 
a 
C/o o.\ QO 
Fig. 3: Six differenc forms of inclusi o n complexes. 
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Key: a- Spherical complex : b - Canal complex : c- Layer complex 
d- ~olecular sieve complex: e- Hol low s pace complex: and 
f- Cylindrical complex.(Taken from Ref. 34). 
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1. Steric requirements 
The steric configurations of the molecules are such that the 
" host " molecule can spatially enclose the " guest " molecule, leaving 
unaffected the bonding systems of the components. This type of fonnation 
is typified by the Schardinger dextrins or cyclodextrins (35). According 
to Cohen and Lach (36), geometrical rather than chemical factors are 
decisive in detennining the kind of guest molecules which can penetrate 
into the cyclodextrin cavity to fonn an inclusion complex. The extent of 
the complex fonnation also depends on the polarity of the guest molecule. 
Because of the cyclodextrins' cyclic structures and relatively large open 
space within each molecule ( 6.0 A0 for alpha, 8.0 A0 for beta, and 
10.0-11 . 0 A0 for gamma ) , they have been reported to fonn complexes with 
different sized molecules (36) . For example, naphthalene is too bulky 
for alpha-cyclodextrin, and anthracene fits only into gamma -cyclodextrin. 
On the other hand, propionic acid fits well with alpha-cyclodextrin , but 
it is too small to fit properly in larger cavitives. Similarly the role 
of molecular dimensions is well demonstrated by the complex fonnation 
with halogenated benzenes (28) . Reaction of the cyclodextrins with 
halobenzenes show that 1:1 complexes may be prepared from chloro, bromo, 
and iodobenzenes. Chlorobenzene reacts only with alpha-cycl odextrin , 
brompbenzene reacts with alpha and beta-cyclodextrins, and iodobenzene 
reacts with beta and gamma-cyclodextrins. According to Va n Hooidonk and 
Breebaart-Hansen (37), the diameter of the cavity in beta-cyclodextrin is 
about 8.0A0 and the size of the benzene ring is about 6.8 A0 ; therefore a 
substituted benzene ring can penetrate into the ring. Certain chemical 
groups or substituents may promote complex fonnation or stability. 
However, the stability of the complex is proportional to the hydrophobic 
13 
characater of the substituents. Thus, a methyl, ethyl, or phenyl 
substituent will increase the complex formation or stability. A methyl 
group in the ortho position to a carbonyl group has a shielding effect on 
the hydrophilic carbonyl group, thereby increasing the hydrophobicity of 
the whole molecule. A similar substitu~nt in the para position has a 
relatively weak effect. Hydroxyl groups hinder complex formation, but 
their hydrophilic effects decrease in the order ortho, meta, and para 
(38). 
2. Complexation by cyclodextrins 
Many drugs are amenable to inclusion complex formation (36 ,39-43 ) 
with cyclodextrins. As shown in Fig. 1, the lining of the cyclodextrins 
cavity is formed by hydrogen and glucosidic oxygen atoms. Therefore, 
this surface is rather apolar (8). In aqueous solution the apolar 
cyclodextrin cavity is occupied by water molecules that are in an 
energetically unfavored state polar-apolar repulsion ) and are, 
therefore readily replaced by an appropriate • guest molecule • that is 
less polar than water. Schematic illustration of the complexation 
process is as shown in the Fig. 4 (8). The small circles represent 
water molecules, the large ones represent cyclodextrin rings. The outer 
surface of the cyclodextrin ring is hydrated, but the water molecules in 
the ring cavity are in an energetically unfavorable condition because of 
the nonpolar surface of the cavity. The hydrophobic part of the 
potential guest molecule is highly hydrated, while the nonpolar aromatic 
ring repu 1 ses the water mo 1ecu1 es. The result of the comp 1 ex formation 
is that the nonpolar part of the guest molecule penetrates into the 
nonpolar cavity, thereby establishing an energetically favorable 
nonpolar-nonpolar interaction, while the protrudi ng hydrophilic part of 
14 
Fig. 4: Schematic representation of the formation of 
cyclodextrin inclusion complexes.(Taken from Ref. 23). 
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the guest molecule outside retains its hydrated shell. Among the various 
changes (44) that occur upon complexation with cyclodextrins the 
following may be of considerable advantage: 
a. Or ganoleptic properties 
b. Conversion of a liquid drug to a solid fonn 
c. Physico-chemical properties 
d. Content unifonnity 
e. Dissolution 
f. Bioavailability 
g. Target organ oriented dosage fonns 
D-Preparation of the inclusion complexes 
The method of preparation of inclusion complexes depends on the 
properties of the guest components (8 ,15 ). The most common procedure is 
to stir or shake an aqueous solution of cyclodextrin (cold or wann) with 
the guest molecule or its solution. Equilibrium is reached with intense 
stirring and slow cooling in a few hours. The guest molecule content 
cannot be increased by repeating the heating and cooling steps . After 
having attained the equilibrium, water can be removed by any one of the 
. fa 11 owing methods. 
1. Solvent evaporation 
Equimolar quantities or up to a ten - fold excess of water soluble 
substances are dissolved in concentrated wann or cold aqueous solutions 
of the cyclodextrins. The inclusion compounds crystallize out on slow 
cooling or eva porati on (45). 
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2. Kneading 
In this case the cyclodextrin is not dissolved, it is kneaded with a 
small amount of water to make a slurry and then guest components are 
added to the slurry of the cyclodextrin. On stirring in a mixer, the 
viscosity of the mixture increases, giving a paste which can be dried and 
powered. 
3. Freeze drying and Spray drying 
These two methods are suitable when fine particles of the complexes 
are desired. Equimolar quantities of host and guest molecules are 
dissolved in a saturated solution of the cyclodextrins. Substances wh i ch 
are not water-soluble can sometimes be dissolved by adding an appropriate 
amount of 28% ammonium hydroxide solution. The solution are then either 
freeze dried or spray dried (8) . 
E-Methods of investi gating the complexes 
1. Solubility 
There are many examples which demonstrate the effect of 
cyclodextrins on the solubility of substances that are sparingly soluble 
in water (39 -43). The solubility of the guest component increases 
linearly with the amount of cyclodextrin added. According to the method 
of Higuchi and his co-workers (46,47) the stability constant and 
stoichiometry can be detennined from the phase s_olubil ity diagram . The 
phase solubility diagram can be constructed by plotting the total molar 
concentration of substrate as a function of the total molar concentration 
of ligand. The ascending linear part of a solubility diagram (Fig.5,A ) 
is generally ascribed to the fonnation of a 1:1 complex and the stability 
constant can be calculated as follows. 
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Fig. 5: Phase so l ubility diagrams 
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K = Slope I S0 (1 - Slope) Eq. (1) 
Where S
0 
is the equilibrium constant of the substrate S, in the 
absence of the ligand L, and thus S0 is equal to the intercept of the 
plot in Fig. 5,A. In some cases, the phase solubility diagram shows a 
plateau region before the descending part of the curve (Fig.5,B), making 
it possible, on the basis of the length of the plateau, to estimate the 
stoichiometry. In such plots, the fonnation of the 1:2 comple x is 
assumed and the stability constant can be calculated by using Eq. 1 and 2 
according to (45,46) as follows: 
Eq. (2) 
Where Lt is the total ligand concentration and St is the equilibrium 
solubility of the substrate in the presence of ligand. 
2. Diffusion 
Gas diffusion provides one of the most direct demonstrations of 
random molecular motion. Without this phenomenon, the perfume industry 
would not exist, and skunks would be much less feared. The diffusion 
properties of cyclodextrin complexes as reported in the literature (8 ,48 ) 
have been used to investigate the complex fonnation by cyclodextrins. 
For example, when indomethacin solution was separated by a semipenneable 
membrane from a buffer solution, a 1:1 equilibrium was observed (47). 
Whereas, when the indomethacin solution was separated by a semipenneable 
membrane from a buffer solution saturated with beta-cyclodextrin a higher 
concentration of indomethacin was observed on the side containing 
cyclodextrin, because, the diffusion rate of the complex was slower due 
to the increase in molecular weight and extensive hydration of 
beta-cyclodextrin. Thus, the concentration of indomethacin was higher on 
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the side containing cyclodextrin, indicating that the majority of the 
indomethacin molecules were fanned in a complex. 
3. X-ray spectroscopy 
Takeo and Kuge (4g,5Q) published X-ray diffraction diagrams of 
several alpha, beta, and gamma cyclodextrins complexes. According to 
their studies, inclusion complexes can be detected quickly and directly 
by X-ray diffraction. If the diffraction pattern does not correspond to 
those of pure components, a true inclusion complex may exist. In the 
case of liquid guest molecules X-ray powder diffraction is the most 
useful method fo r the detection of inclusion complex fonnation . Since 
the liquid guest molecules produce no diffraction pattern at all, if the 
diffractogram differs significantly from that of uncomplexed 
cyclodextrin, fonnation of a crystal lattice of a new type and complex 
fonnation can be established. Single X-ray structure analysis is the best 
method for detecting complex fonnation (15) . 
4. Infrared (IR) spectroscopy 
The complex fonnation may be proved by IR spectroscopy, the 
characteristic bands of cyclodextrin, which represent the overwhelming 
part of the complex, are influenced by complex fonnation . Bands due to 
the included part of the guest molecule are generally shifted or their 
intensities are altered (51). 
5. Differential scanning calorimetry (DSC) 
In certain cases cyclodextrins complex fonnation can be proved by 
DSC. Kurozumi ~ (51) have found that freeze dried mefenamic acid 
gives at 232°c an endothennic peak; its mechanical mixture with freeze 
dried beta cyclodextrin gives the same peak at the same temperature . But 
the beta cyclodextrin complex prepared by freeze drying or 
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crystallization from water does not give any peak . This behavior is 
usually characteristic of the inclusion complexes. 
6. Proton magnetic resonance (PMR ) spectroscopy 
Demarco and Thakkar (52) investigated cyclodextrin inclusion complex 
formation by PMR spectrometry. In their study, they observed that the 
beta-cyclodextrin spectrum was shifted upfield in the presence of guest 
molecules. According to Demarco and Thakkar, if the guest molecule is 
accommodated in the cyclodextrin cavity, then the hydrogen atoms located 
in the interior of the cavity (C-3-H and C-5-H) will be considerably 
shielded by the guest and hence the signal will be shifted upfield. 
Whereas, the hydrogen atoms on the outer surface (C -2- H, C-4- H, and 
C-6-H) will not be affected by the guest molecule, hence the signals of 
those protons will remain unchanged. The cyclodextrins contain six, 
seven, and eight units of glucose, and due to the multiplicity of (C -3 -H 
and C-5 - H) protons located in the interior of the cavity, an exact 
evaluation was impossible. 
7. Other methods 
Inclusion of a guest molecule can also be investigated by monitoring 
changes in its conductivity {53- 55), apparent changes in its basicity 
(56,57), changes in the optical spectra, thermodynamic parameters, etc. 
(8,58). 
F-Present and possible future potential of cyclodextrins in 
pharmaceutical products. 
1. Organoleptic properties 
It is possible to improve the organoleptic properties of drug 
molecules by inclusion complexation with cyclodextrins (8,15,59,60). For 
instance, femoxetine is a selective serotonin uptake inhibitor with 
21 
antidepressant properties (59}. This compound is used as a water soluble 
salt, but it has a very bitter taste which hinders the development of 
oral liquid formulations. A study was undertaken to obtain a liquid 
formulation of femoxetine with acceptable oraganoleptic properties 
through inclusion complexation with the beta -cyclodextrin (59}, and the 
results were favorable. 
2. Conversion of a liquid drug to a solid form 
Liquid compounds can be converted into the solid form by inclusion 
complexation with cyclodextrins (61). Organic nitrates have been used 
for a long time for the treatment of angina pectoris, and they are still 
widely used. For example, one of the best known drugs is 
nitroglycerin,which is a highly explosive liquid drug and therefore 
cannot be tabletted. However, by complexation with cyclodextrin, it is 
possible to convert the drug into solid form and tablets can be 
manufactured (61). In addition, complexes of unsaturated fatty acids, 
ascaridol, clofibrate, methyl pentynol, etc . , have been converted into a 
solid form by complexation with cyclodextrins (62,63). These reports 
suggest that the product obtained in this way can be used to manufacture 
t ablets. 
3. Physico-chemical stability 
Inclusion complexation can be regarded as micro-encapsulation, 
because each guest molecule is surrounded by cyclodextrin molecules and 
is thus, from the microscopical point of view, encapsulated. This 
phenomenon can be exploited by industries which manufacture drugs, 
foodstuffs, plant protective agents, etc. The use of cyclodextrin 
complexes in indust r ies, particularly in the pharmaceutical field, can 
result in the following improvements in stability. 
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a. Stabilization of light or oxygen sensitive substances 
The extremely labile vitamin 03 (cholecalciferol) should be 
mentioned here; heat, light, and oxygen all increase the degradation of 
vitamin 03 by oxidation, but these effects can be inhibited by the 
inclusion complexation (64 ,65 ). Similarly, inclusion of vitamin A in 
alpha-cyclodextrin increased its stability against heat (66). The 
sensitivity to light of clofibrate (67) and guaiazulene (68) are reduced 
by the inclusion complexation with the cyclodextrins. 
b. Modification of the chemical activity or stability of guest molecules 
Lach and Chin (41) have reported that the alkaline hydrolysis of 
benzocaine becomes considerably slower in the presence of 
beta-cyclodextrin. In 1 % beta-cyclodextrin solution the half- life of 
benzocaine is increased five-fold . Chin, Chung, and Lach (69) studied in 
detail the alkaine hydrolysis of esters of various aminobenzoic acids and 
acetylsalicylic acid. 
It was found that the rate of hydrolysis decreased when inclusion 
was complete. If, however, incorporation of the guest molecule was 
incomplete then the hydrolysis rate increased. Since the inclusion was 
complete, the rate of hydrolysis of para, meta, and ortho aminobenzoates 
was decreased by the beta-cyclodextrin. Beta-cyclodextrin has also been 
shown to have a stabilizing influence on procaine, atropine, aspirin, and 
phenylbutazone (70) . Indomethacin is stabilized by beta-cyclodextrin but 
not by alpha-cyclodextrin (71) . In addition, there are many reports on 
the modification of the chemical activity or stability of guest molecules 
by inclusion complexation with the cyclodextrins (8 ,15, 72,73). 
c. Fixation of very volatile substances 
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A reduction in the volatility can be demonstrated by an increase in 
the boiling point of both liquids and solids that sublime. Uekama et al. 
(67) demonstrated the reduction in volatility of drugs forming inclusion 
complexes by differential thermal analysis and thermogravimetry. They 
used this technique to show the reduced volatility of the clofibrate 
beta-cyclodextria complex. The differential thermal analysis of 
clofibrate gave an endothermic peak around 150°C corresponding to the 
boiling point. This endothermic peak disappeared with the formation of an 
inclusion complex . Fu r thermore, the thermogravimetry curves showed 
significant reduction in the volatility of clofibrate as a result of 
complex formation. Uekama~(74) obtained similar results with the 
complexes of derivatives of cinnamic acid and beta -cyclodextrin, and the 
complexes of benzaldehyde and alpha, beta, and gamma-cyclodextrins (75). 
Szejtli~ (76) produced beta -cyclodextrin complexes of 25 different 
aromatic substances, and the solid complexes obtained enabled better 
handling of the products . They contained all the constituents of the 
original substa nc es. Nakai~ (77) used the thermogravimetry method 
to study the volatility of the physical mixtures, the ground mixtures, 
and the inclusion complexes of parahydroxybenzoic acid with the alpha and 
beta-cyclodextrins. The sublimation of parabydroxy benzoic acid was 
considerably reduced by the inclusion complex. The inclusion complex with 
alpha -cyclodextrin showed the greatest reduction of sublimation, most 
probably due to a more tight fit within the cavity of alpha-cyclodextrin 
molecule . 
4. Content uniformity 
This United States Pharmacopeia (USP) content uniformity test is 
designed to establish the dose equivalency of solid dosage forms. The 
24 
content unifonnity of a solid dosage fonn cannot be better than that of 
the granulation of those dosage fonns. There are three possible factors 
inherent in the tablet manufacturing process which may cause difficulties 
in achieving a good content unifonnity namely: (a) nonunifonn 
distribution of drug throughout the powder mixture or granulation, (b ) 
segregation of the powder mixture or granulation during the manufacturing 
process, and (c) tablet weight variation . These three fact ors may cause 
more diffculties in achieving a good content unifonnity with potent 
low-dose drugs (oral contraceptives, etc.). It is not difficult to 
comprehend why a perfect physical mixture never occurs or why the 
segregation occurs with powder mixtures intended for direct compression 
or why with wet granulations drug migration is likely . Some or all of 
these problems may be alleviated by complexation with cyclodextrins. If 
a drug gives a stable complex, then the crucial question is the required 
dose. In addition to the required dose (active ingredient ) , tablets 
contain a number of inert materials. These include diluents, binders, 
distintegrants, and lubricants. If the required dose is 50mg or more it 
may not be difficult to distribute the active ingredient unifonnly in the 
inert materials to compress a tablet with suitable weight. However, if 
the required dose is a few milligrams or less, it is very difficult, if 
not impossible, to achieve a good content unifonnity, since more than 90% 
of the tablet weight is filled with the inert materials . 
By the inclusion complexation technique, a drug can be dispersed at 
a molecular level, and usually the drug content in the inclusion complex 
is in the range of 15- 25% (8). If the required dose is a few milligrams 
or less then it may not be difficult to disperse unifonnly lOOmg of the 
complex instead of 15 or 25mg of drug into the inert materials. By this 
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type of molecular dispersion it is conceivable that some or part of the 
previously mentioned factors may be reduced in achieving a good content 
unifonnity of potent low dose drugs. 
5. Dissolution 
The number of papers and patents describing drug -cyclodextrin 
complexes, their stability, dissolution rate, bioavailability, and 
phannacological effects has been growing rapidly in phannaceutical 
research (8,15,23). Solubility changes have been observed as a function 
of complexation and substantial increases in drug stability have also 
been reported (78,84) . These reports als~ showed that the improved 
aqueous solubility by complexation resulted in an enhancement of the 
dissolution rate of various drugs (78,84}. The dissolution -absorption 
process of an orally administered drug can be approximated by the 
following simple kinetic model. 
D Kd GI Kr B 
~~~~~- -~~~~~-
Eq. (3) 
Where D is the oral dose of the drug, GI is the concentration of drug 
dissolved in the gastrointestinal tract, B is the concentration of drug 
in blood; Kd represents the rate constant of dissoltuion, and Kr 
represents the rate constant of absorption . 
When Kd .( Kr, then the dissolution is the rate detennining step in 
the drug absorption . In such cases Kd may be increased by complexing 
with cyclodextrins. For example, the dissolution rate of proscillaridin 
complexes was much greater than that of proscillaridin itself (85}. 
Interaction of digitalis glycosides with cyclodextrins has been reported 
(86). It has been clearly shown that the dissolution rate (in acidic 
medium) of the complexed fonn of digoxin is about 100- fold more than that 
of digoxin itself. In addition, during the dissolution experiments, the 
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simultaneous conversions of digoxin to hydrolysis products were also 
follwed by HPLC. The rapid dissolving form of the complex showed the 
reduced decomposition compared to that of digoxin alone. The dissoltuion 
of menadion (vitamin k3), and its beta-cyclodextrin complex in water was 
found to be increased by 10 to 12- fold (23). Improved dissolution 
characteristics of acetohexamide has been reported by complexation with 
cyclodextrins (87). Similarly, there are many examples which clearl y 
demonstrate that complexation with cyclodextrins has improved aqueous 
solubility ( 78-84 ) and dissolution rate of various drugs 
(8,71,74,88,89) . 
Dissolution tests have two possible uses. They may, as indicated in 
the above discussion, be predictive of the rate and extent of drug 
entering a patient's blood stream . However, a quantitative relationship 
between dissolution and bioavailability can not be assumed for any given 
drug; such a relationship is not necessarily simple . Secondly, 
dissolution tests have value as a method of controlling batch to batch 
variation. USP XX requires dissolution tests for virtually all 
conventional solid oral dosage forms. Thus to some extent dissolution has 
become an end itself. 
6. Bioavailability 
Bioavailability of a drug product is defined as the rate and extent 
of absorption. Biological availability is determined by comparing blood 
levels produced by a test product with those produced by an intravenous 
injection, an aqueous solution, and a commercial dosage form of the drug. 
When making comparisions of the biological availability of products, 
normally the following three parameters are determined. 
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a. Maximum plasma concentration 
b. Time to reach maximum plasma concentration 
c. Area under the curve 
Whenever a drug is administered by the oral route, there is a 
possibility that part of the dose may not reach the blood due to 
incomplete absorption (90 ,91 ). This result may arise for a variety of 
reasons, such as poor dissolution of the drug in the gastrointestinal 
fluids (92-95), first-pass liver metabolism (90) , etc. In instances where 
bioavailability is incomplete, the ratio of oral to intravenous blood 
level curve areas is less than unity (96). Hence, a great deal of 
investigation is required to appreciate fully the role of the 
gastrointestinal tract in drug absorption. For example, a thorough 
investigation is required with respect to interactions of drug with 
dietary factors, physiological and physico-chemical factors (97) , etc. 
In this section, enhancement of bioavailability by cyclodextrin inclusion 
complexation is discussed. Improving the absorption of drugs may be one 
of the important practical applications of cyclodextrin complexes. 
Following the oral administration of the drug, practically no 
cyclodextrin is absorbed (23) . Cyclodextrin is onl y a carrier agent; it 
transports the lipophilic guest molecule through an aqueous milieu to the 
lipophilic membrane of cells in the gastrointestinal tract. There the 
guest molecule is absorbed, since the membrane has a higher affinity for 
a lipophilic guest molecule than the cyclodextrin itself (23). The 
relationship of complexation to the absorption and distribution of a drug 
in the body is well documented in the literature (98). 
The dissociation and association reactions of cyclodextrin complexes 
in solution are very rapid, and the equilibrium of free and complexed 
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drug is established instantaneously (23,99). This may perhaps be used to 
improve medication through the use of tablets containing both the 
hydrophobic drug complexed to cyclodextrin and the same drug in the free 
form. The former would enter the circulation very rapidly, while 
dissolution of the. latter would occur slowly and form a drug depot (100). 
Andersen, F.M., et al. (59), reported the absorption of femoxetine 
(a selective serotonin uptake inhibitor with antidepressant properties ) 
in five human volunteers. In this study, five subjects were given six 
sugar-coated tablets each containing lOOmg of femoxetine salt and 
femoxetine beta-cyclodextrin complex formulated as a suspension. The 
dose of the suspension was equivalent to 600mg femoxetine salt. The 
study was single dose and cross -over design. Each volunteer was given 
the doses with an interval of at least two weeks between each 
administration. The blood level was determined by gas chromatography. 
The area under the blood level curve (AUC) was calculated using the 
trapezoidal rule. The AUC for the cyclodextrin complex varied from 23 to 
96 ng"h"kg"m1- 1·mg-1, while the corresponding values were 30 to 120 
ng"h"kg"m1-1·mg-l for the sugar-coated tablet. There was statistically 
no difference between the AUCs for the two formulations. The maximum 
plasma concentration was reached within one to four hours. The 
variations were similar to those observed in AUCs . In conclusion, the 
bioavailability of femoxentine beta-cyclodextrin complex, formulated as a 
suspension, was found to be similar to that observed from a sugar -coated 
tablet of femoxetine salt. However, this study would have been more 
meaningful if the results of the above study had been compared with (a ) 
femoxetine tablet, preferably the uncoated tablet, or {b) with the same 
dosage form. 
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In vivo absorption studies were undertaken to find if the in vitro 
dissolution enhancement of digoxin from its cyclodextrin complex 
increases in the absorption of the drug (86). In this study, digoxin 
tablets containing 100/ug digoxin and its gamma -cyclodextrin complex 
containing 100/ug digoxin were administered orally to six dogs. The 
concentration of digoxin in the plasma sample was determined by enzyme 
immunoassay. The maximum plasma concentration of 0. 90 ~ 0. 14mg/l at 45 
minutes was obtained. This concentration level was three times higher 
than that of digoxin alone. The area under the plasma concentrati on time 
curve of the complex up to 24 hours was found to be 5. 4 times as much as 
that of digoxin alone. In addition, the area under the curve of the 
complex containing 50/ug of digoxin was found to be superior to that of 
100/ug digoxin alone. Thus, the improved bioavailability of digoxin by 
gamma-cyclodextrin complexation suggests a decrease in doses and fewer 
side effects in oral digitalis glycoside therapy. 
Ukema, K., ~- (87), studied the hypoglycemic action of 
acetohexamide-beta-cyclodextrin complex with that of acetohexamide by 
oral administration in five male rabbits . The complex equivalent to 
30mg/kg of acetohexamide was administered as a suspension in 80ml of 
water. In each case at least seven days were allowed between each blood 
glucose estimation. The reduction in the blood glucose level was 
obse rved in the system co ntain ing the complex. When results were 
compared using paired Student's t-test, the difference was found to be 
statistically significant . However, it is the opinion of the author of 
this thesis that, a detailed study should be made to elucidate the 
absorption mechanism of cyclodextrin complex . 
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Seo, H. , et al. (88), studied in vivo absorption of spironolactone 
(SP) to determine whether or not the enhanced in vitro dissolution of SP 
from its beta or gamma -cyclodextrin complex increased the GI absorption 
of the drug. SP is a steroidal aldosterone antagonist that is widely 
used fn the treatment of hypertension, edematous states, etc. Because of 
its low solubility in water, the bioavailability of the SP preparation is 
known to vary significantly among brands and batches (authors reported 
with proper references). In the above study, four male beagle dogs were 
administered orally a capsule containing (5mg/kg of body weight as SP), 
the drug, and its complex. The administration sequence was based on a 
crossover design with an interval of more than one week. The plasma 
concentration was determined by high pressure liquid chromatography. The 
standard curve range was from 20 to 200ng/ml. The beta and 
gamma-cyclodextrin complexes produced a maximum plasma concentration of 
103_: 28"3ng/ml and 131.!_14 "7ng/ml. at 90-minutes, respectively . These 
concentrations were about two to three times higher than that of SP 
alone. Similarly, the areas under the curves of complexes up to 24 hours 
were found to be more than two times greater than SP alone. The authors 
did not report any significant difference in time to reach the maximum 
concentration (Tmaxl· It is the authors' opinion of the above study 
that the enhanced bioavailability of SP produced by beta or 
gamma-cyclodextrin complexation makes possible the use of a lower dose 
with fewer side effects in (o ral ) SP therapy . 
Tsuruoka, M., et al. (95) , studied the absorption of freeze dried 
phenytoin, phenytoin and its beta -cyclodextrin complex in a group of four 
female beagle dogs. Dogs were given orally 300mg of phenytoin and its 
complex equivalent to 300mg phenytoin. The concentration of phenytoin 
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was detennined by gas chromatography. There was a twofold increase in 
the area under the curve of the blood level. Further, it was reported in 
this study that increased bioavailability of phenytoin by means of 
beta-cyclodextrin complexation suggested the possibility of smaller doses 
and fewer side effects in phenytoin therapy. The details of the studies 
such as, statistical evaluations, etc., were not clearly reported. 
Indomethacin and its beta - cyclodextrin complex were administered 
orally to rats (100). The rats were treated orally with 30mg/kg 
indomethacin and its complex equivalent to 30mg of indomethacin. 
Indomethacin level in the blood was measured by high pressure liquid 
chromatography. The maximum blood level was found between 1 and 4 hours 
after treatment . It was approximately 25% higher in the case of the 
complex. The details of the experimental design, such as number of 
animals, statistical evaluations, sensitivity of the assay method, etc., 
were not reported; however, based on the reported data it appears that 
the beta-cyclodextrin complex may be used to increase the bioavailability 
of indomethacin. 
Tokumara, T., et al. (101), studied the bioavailability of 
cinnarizine with beta-cyclodextrin in three male beagle dogs. Two 
tablets of cinnarizine and its complex containing 2Smg of cinnarizine in 
each tablet were administered orally to dogs . The concentration of the 
drug in the plasma was detennined by high pressure liquid chromatog raphy. 
In less than an hour the complex gave the maximum plasma level of 166.9 _: 
22.4ng/ml, which was 8.6 times as high as that of cinnarizine alone. 
This initial increase in drug absorption might be due (according to the 
authors) to the 30 times higher dissolution rate of the complex than that 
of intact cinnarizine alone; however, there was no significant 
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difference between the areas under the plasma concentration-time curves 
(AUC). The AUC of cinnarizine and its complex up to eight hours was 
267.2 .:!: 102.9 and 374.2 .:!: 97.2ng · h/ml, respectively. This might be due 
(authors' opinio n) to the large stability constant of the complex, 
estimated to be approximately 6.2 x 103M- l in water at 20°c. 
Fremming and Weyermann (102), investigated the absorption of an 
orally administered salicylic acid and its beta -cyclodextrin complex in 
ten human volunteers (7 male and 3 female). The percentage of absorbed 
salicylic acid at a given time was reported as follows. From salicylic 
acid in one hour 24.8%, whereas from the complex 43.0% appeared in the 
blood; in two hours the values were 56 .8% and 82.5%, respectively. 
Hence, a significant difference in blood level was reported . 
Nambu, N. , ~· (103), have reported the bioavailability of the 
powdered inclusion compounds with beta-cyclodextrin of four kinds of 
nonsteroidal anti - inflamatory drugs and the freeze dried drug alone. 
These drugs were flufenamic acid (FFA), ibuprofen (! PE ) , ketoprofen (KPF ) 
and indomethacin (IMC). This study was done on three healthy albino 
rabbits and six healthy male beagle dogs. The drugs were administered to 
the stomach of each rabbit through a sonde, using fresh suspensions 
containing lOOmg of FFA, 200mg of !PF, lOOmg of KPF, and 50mg of IMC. In 
the case of the beagle dogs, the cross-over method was used with an 
interval of one week. The dogs were administered lOOmg of KPF orally as 
a powder. The bioavailability results of only this drug in dogs were 
reported. The plasma concentration of FFA was determined by fluorescence 
spectrophotometer, the concentracitons of !PF, KPF, and IMC were 
determined by gas chromatography. The details of the analytical methods 
and conditions such as sensitivity, reproducibility, accuracy, were not 
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reported. The FFA inclusion compound gave a high blood level compared 
with the simply freeze dried drug. The actual blood level was not 
reported. It was observed or estimated from the blood level curve that 
the maximum plasma concentrations of FFA freeze dried inclusion compound 
and freeze dried FFA were approximately 6ug/ml . and 2.5ug/ml, 
respectively. The time to reach maximum plasma concentration was 
approximately one hour. However, there was a double maxima, and it is in 
the authors' opinion that further investigation is required to elucidate 
the double maxima on the blood level curve. A similar effect was 
observed in the case of IMC. In the case of !PF the freeze dried complex 
gave a high blood level compared to the simply freeze dried drug. The 
exact plasma concentration was not reported. Among the four drugs, KPF 
gave the highest blood level, and no double maxima phenomenon was 
observed. The KPF recovery in the urine was 60.5% for the freeze dried 
inclusion compound and 40.0% for the simply freeze-dried drug. In order 
to confirm the results obtained in the rabbits, a bioavailability study 
was carried out using beagle dogs. In the area under the curve up to four 
hours after administration the ratio was found to be 1.52 to 1.00 for the 
inclusion compound KPF against the simply freeze dried drug. There was a 
significant difference in the blood levels up to four hours, as 
determined by Student's-t-test. 
Cyclodextrin complexes are not necessarily limited to oral use. 
Cyclodextrin complexes in suppositories have improved dissolution and 
bioavailability. For instance, Iwaoku, R. ~- (104), studied the 
absorption of phenobarbital from suppositories containing 
beta-cyclodextrin. In this study, five male albino rabbits were used, 
and a test suppository containing approximatel y 50mg phenobarbital was 
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inserted into the rectum. An interval of more than two days was all owed 
prior to the next experiment. Assay of phenobarbital in blood samples 
withdrawn from the ear vein was performed by gas chromatography; however, 
details of assay sensitivity, reproducibility were not reported. Blood 
levels of the drug containing the complex were muth higher during the 
initial three hour period. There was a statistically significant 
difference in the extent of absorption compared to the rate of 
absorption. 
The literature is replete with other reports on application of 
cyclodextrin complexes for the bioavailability of various drugs 
(105-117). 
Summarizing the biological availability data, the author of this 
thesis feels as follows: Some of the published data demonstrate 
unambiguously that the cyclodextrin inclusion compounds are shown to 
improve bioavailability (in animals as well as in humans) of certain 
drugs . However, some of the reported studies are not well designed or 
may lack certain essential details; hence, reported results should be 
accepted with some reservations. However, there is a substantial number 
of papers that show that orally administered cyclodextrins are safe and 
useful in the enhancement of bioavailability. There are some cases in 
which it has been shown that cyclodextrins are not only useful in the 
enhancement of bioavailability but also in the reduction of side effects . 
It has been reported that for digoxin there was a correlation between..!..!! 
vitro dissolution enhancement by complexation and in vivo absorption in 
animals. 
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7. Target organ oriented dosage forms 
It is understood by the author of this thesis that certain research 
groups in the U. S. pharmaceutical industry are exploring the possibility 
of developing drug delivery systems containing cyclodextrins for target 
organ oriented dosage forms. In particular, they are focussing their 
attention on systems containing drugs administered by the parenteral 
route for the treatment of cancer. 
G-The development process for a new pharmaceutical dosage form 
Today the discovery, development, and marketing of a new drug is a 
time consuming and costly procedure. The development of a new drug 
usually begins with a decision made by the scientific advisory board of a 
pharmaceutical company. When the decision is made to create a drug for 
use in a particular state, virtually all departments within the company 
or institute become involved in its development, such as chemical and 
biological research, pharmaceutical development, regulatory department, 
etc. This multifaceted approach is frequently so complex that for this 
reason at first only regulatory and technical aspects are dicussed. 
1. Regulatory aspects 
When the Federal Food, Drug, and Cosmetic Act of 1938 was passed, a 
new era of drug development began. Prior to the institution of clinical 
testing in humans, a Notice of Claimed Investigational Exemption for a 
new drug must be filed with the Food and Drug Administration (FDA ) by the 
sponsor . This form is also referred to as an IND or investigational new 
drug. These regulations appear in section 505 of the act (118-120). A " 
new drug " is one not presently recognized by experts in the field of 
clinical pharmacology to be safe and effective based on currently 
available clinical evidence. All the definitions of a new drug may be 
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found in the FDA consumer (121). The Supreme Court held in FDA: Prem that 
" new drug " could include a new· dosage form, not just a new chemical 
entity. Originally a sponsor could begin clinical trials immediatel y 
after filing his IN D; today, however, the regulations provide for a 
30-day waiting period after which, if the FDA has not responded 
negatively, the clinical trials may commence. The sponsor, upon 
completion of a sufficient amount of clinical work to demonstrate the 
safety and effectiveness of the new drug for the use or uses for which it 
is intended, may then submit a new drug application (NOA) to the FDA. 
This application must include: (a) detailed reports of the preclinical 
studies, (b) reports of all clinical studies, (c) information on the 
composition and manufacture of the drug and on the controls and 
facilities used in its manufacture according to current good 
manufacturing practices (CGMPs ) , good clinical practices (GCPs ) , etc ., 
(d) samples of the drug and its labeling. Once a new drug application 
(NOA) is approved, any change in the manufacturing, packaging, or other 
physical properties of the drug that may have an effect on safety and 
effectiveness must be covered by a supplemental new drug application. 
Because of today's myriad regulations, the NOA submission has become a 
compilation of information that could be compared in size to any one of 
the well known encyclopedias. Currently, the period f rom the time of 
synthesis of a compound to its release for marketing is genera l ly some 
ten-year or longer (122-124 ) . The FDA does try to minimize duplication of 
effort in preparing application for drugs about which some of the needed 
information is already available, by allowing use of that informati on 
with assurance that the new product will be equivalent to established 
marketed products. In this regard, the detailed description of the 
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concept of an abbreviated new drug application (ANDA) was published in 
1975 (125). Unlike the NOA, which requires submission of well controlled 
clinical studies to demonstrate effectiveness, data to show saftey, and 
detailed description of the manufacturing and packaging of a drug as well 
as stability data, the ANDA requires the following: a description of the 
components and composition of the dosage form to be marketed; brief 
statements that identify the place where the drug is to be manufactured; 
the name of the supplier of the active ingredients; an outline of the 
methods and facilities used in the manufacture and package, etc. (126). 
The purpose of the ANDA procedure is to eliminate uncessary and costly 
animal and human experimentaion and to make all drug substances not 
covered by patents readily available to the consumer in a competitve 
market. As discussed in the sections B and C of this introduction, 
detailed studies of the metabolism and toxicity have shown that the 
orally administered beta-cyclodextrin is innocuous. The cyclodextrins 
administered in high doses subcutaneously, intraperitoneally, or 
intravenously can induce renal damages in the rat, but at lower doses the 
compound can be administered without any ill effects (20,21). Discussion 
with people from the pharmaceutical industry suggests that several 
companies are working on the formulation and evaluation of pharmaceutical 
products containing cyclodextrins, while other companies are waiting to 
see a cost reduction and improved availability of cyclodextrins before 
proceeding with their studies . For instance, Squibb is evaluating 
parenteral administration of a pharmaceutical product containing 
cyclodextrin, while in Japan prostaglandin El is now commercially 
available ;n the form of its cyclodextrin complex (15,23). 
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2. Technical aspects 
The development of a pharmaceutical formulation involves a number of 
considerations, such as, physico-chemical stability, availability of 
materials, cost factors, equipment, proper facilities, etc. As previously 
mentioned in section F of this introduction, cyclodextrins can be used 
for the preparation of inclusion compounds which demonstrate improved 
physico-chemical stability, dissolution, bioavailability, etc., of 
pharmaceuticals. At present, even though the cyclodextrins are somewhat 
expensive for large scale use because of their monumental potential in 
various fields, in the future the cost of the cyclodextrins may well 
become more reasonable for pharmaceutical purposes. When a formulator is 
called on to develop a suitable dosage form for a new drug, he or she 
would first consider solid dosage forms. Formulation and stability 
problems arise less frequently with solid dosage forms than with liquid 
pharmaceutical preparations (127). However, the formulations of solid 
dosage forms are not an easy task. The development of a solid dosage form 
can be traced through three stages; formulation design, process 
development, and process validation, prior to actual production. The 
process development and validation are often considered as a separate 
stage in dosage form development. The technical aspects of solid dosage 
forms are as follows. 
a. The determination of chemical and physical characteristics of the 
active ingredient and its compatibility with potential formulation 
ingredients. 
b. The determination of formulation tolerances, flow characteristics, 
compressibility, selectivity of methods of manufacturing, etc. 
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c. The evaluation of the final product to meet requirements for a variety 
of properties such as, appearance, hardness, friability, weight 
variation, disintegration, dissolution, consumer acceptability, etc. 
Some or all of these evaluations ought to be done in order to 
develop a solid dosage fonn. Whe n a fonnulator faces . the problem of 
getting sufficient quantity of active ingredients, as is quite common, an 
innovative modification of techniques to a semi-micro scale may well be 
needed. In this thesis some of these problems are considered and 
possible solutions are developed. 
H-· Objectives of this study 
As has been noted in previous section of this introduction, the 
literature has a wealth of publications which report on the ability of 
cyclodextrins ( especially beta -cyclodextrin ) to fonn inclusion 
compounds with a wide variety of drugs and other guest molecules . 
Cyclodextrin complexes have attracted a number of different types of 
scientific study ( for example, some biochemists have used cyclodextrin 
complexes as a model for evaluating enzyme activity) . A number of 
possible phannaceutical applications of cyclodextrins have been 
suggested . In particular, there are abundant data which clearly 
demonstrate that, for some drugs, chemical or physical stability, 
organoleptic properties, and dissolution can be radically im~roved by use 
of cyclodextrins. 
The literature is replete with papers which report laboratory 
studies of the interaction of a wide variety of drugs with cyclodextrins. 
The number of interaction studies described in the literature is almost 
equal to the number of researchers in the phannaceutical field. However, 
there is a distinct paucity of papers which describe how such .inclusion 
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compounds can be conveniently incorporated into pharmaceutical dosage 
forms. From the pharmaceutical point of view , if an inclusion compound 
with cyclodextrins is provided i n the solid powdered form, it may be more 
widely used, since it is especially convenient for oral administration. 
However, there have been very few reports published concerning t~e 
inclusion compounds obtained in the solid powdered form. Additionally , 
although a number of methods are described in the literature for the 
production of the drug-cyclodextrin inclusion compounds at the laboratory 
level, little attention appears to have been given to producing these 
products at the pilot scale or manufacturing level. The success of a new 
drug or drug-complex depends on the development of practical formulations 
which can be readily processed by an economically viable method for 
general use. 
The objectives of the present study are: 
1. To prepare some drug-betacyclodextrin inclusion compounds in the solid 
powdered form by various techniques, with a view to providing information 
concerning which methods are most likely to be of use commercially. 
2. To investigate properties of the complexes in aqueous solution and in 
solid state. 
3. To evaluate the preformulation properties of inclusion compounds , such 
as, bulk properties, flow cha racteristics, compressibility , dissolution, 
etc. 
4. To accomplish preliminary la boratory scale-up studies . 
5. To prepare and evaluate potentially commercially acceptable 
pharmaceutical dosage forms of selected drugs. 
The drugs selected for this study are ampicillin, phenobarbitone, 
and phenytoin. These compounds have a wide range of pharmacologic, and 
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physico-chemical properties and therefore allow us to explore a variety 
of different formulation and processing problems . 
Data published by other authors ( post Jan.1982 ) are discussed, 
together with the data obtained in this study in the Result and 
Discussion section of this thesis. It is noteworthy that despite the wide 
interest in the pharmaceutical exploitation of cyclodextrins there is at 
the time of writing ( June 1985 ) still no pharmaceutical product 
containing cyclodextrins approved for marketing in the U. S. 
I I EXPERIMENTAL 
A-Materials 
1. Drugs 
Ampicillin anhydrous (43F-0746) 
(S igma Chemical Company, St. Louis, MO) 
Phenobarbitone (Gl9204F04) 
(Amend Drug and Chemical Co . , Irvington, NJ} 
Phenytoin (63F-3449} 
(Sigma Chemical Company, Co., Irvington, NJ) 
2. Fonnulation components and chemicals 
Acetonitrile (724629) 
(Fisher Scientific Company, Fair Lawn, NJ) 
Ammonium hydroxide (E701005 ) 
(Allied Chemical Division, Morrison, NJ) 
Boric acid (710413) 
(Ame nd Drug and Chemical Co., Irvington, NJ) 
Citric acid (z6698M31 ) 
(Amend Drug and Chemical Co., Irvington, NJ) 
Colloidal magnesium alluminum silicate (82470) 
(R .T. Vanderbilt Compa ny Inc . , New York, NY) 
Dicalcium phosphate dihydrate (9187) 
(Encompress , Edward Mendell Co ., Cannel, NY) 
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Dimethylacetamide (33 F-0831 ) 
(S igma Chemical Company, St. Louis, MO 
Ethanol 
(U.S. Industria l Chemicals, Inc., Newark, NJ) 
Glycerol (J26123K29) 
(Ruger Chemical Co., Irv ington, NJ ) 
Hydrochloric acid (026490 ) 
(E.I. Dupont De Nemours & Co., Inc ., Wilmington, DE ) 
Magnesium carbonate (27061M31) 
(Ruger Chemical Co., Irvington, NJ ) 
Magnesium stearate (772716) 
(Fisher Scientific Company, Fair Lawn, NJ) 
Methanol (743275 ) 
(Fisher Scientific Company, Fair Lawn, NJ) 
Methyl cellulose 1500cps (MM121926c ) 
(Ruger Chemical Co., Irvington, NJ 
Microcrystalline cellulose (1 4261 ) 
(Avicel PH 101, FMC corporation, Philadelphia, PA ) 
Monobasic potassium phosphate (722964 ) 
(Fisher Scientific Company, Fair Lawn, NJ) 
Peppennint oil (J26477Ml6 ) 
(Amend Drug and Chemical Co., Irvington, NJ ) 
Phosphoric acid (y-115 ) 
(All ied Chemical Division, Morrison, NJ) 
Polyethylene glycol 200 (B3459A26 ) 
(Ruger Chemical Co ., Irvington, NJ) 
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Polyethylene glycol 300 (Jl9526Bl0) 
(Ruger Chemical Co., Irvington, NJ) 
Polyethylene glycol 400 (Dl4508k06) 
(Ruger Chemical Co., Irvington, NJ) 
Potassium chloride (950373) 
(J.T. Baker Chemical Co., Phillipsburg, NJ) 
Propylene glycol (025395) 
(J.T. Baker Chemical Co . , Phillipsburg, NJ) 
Sodium hydroxide (720859) 
(Fisher Scientific Company, Fair Lawn, NJ) 
Sodium Starch glycolate (2166 ) 
(Explota b, Edward Mendell Co., Carmel, NY) 
Sorbitol (H22101 P20 ) 
(Ruger Chemical Co., Irvington, NJ) 
Spearment oil (H l8261!10 ) 
(Amend Drug and Chemical Co., Irvington, NJ) 
Sugar 
(Sweet Life Products Corp. , Suffi e 1 d, CT) 
3. Equipment 
Apple Computer and Printer 
(Apple Computer, Cupertino, CA) 
Brinkmann Mini Spray Drier 
(B rinkmann Instruments, Inc., Westbury, NY) 
Carver Laboratory Press 
(Fred S. Carver Inc., Menobonel Falls, WI) 
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Chart Strip Recorder 
(Cole- Parmer Instrument Company, Chicago, IL) 
Constant Temperature Refrigerated Bath 
(Blue M Electric Company, Blue Island, IL) 
Differential Calorimeter 
(Perkin Elmer, Norwalk, CT) 
Erweka Hardness Tester 
(Erweka Apparatabau, W. Germany) 
Fi sher-Wheel Sieve Shaker 
(Central Scientific Company, Chicago, IL) 
Fixed Wavelength Detector 
(Water Associates, Milford, MA) 
Hull Freeze Drier 
(Hull Corp. Hatboro, PA) 
Infrared Sjpectrophotometer 
(Perkin Elmer, 457, Grating Infrared Spectophotomer, NJ) 
Kitchen Aid Mixer 
(The Hobart Mfg . Co., Troy, OH) 
Markson Digital pH meter 
(Markson, Science Inc . , Delmar, CA) 
Mettler Balances 
(Mettler Instrument Corporation, Princeton, NJ) 
Mettler Digital /Analog converter 
(Mettler Instrument Corporation, Princeton, NJ) 
Microscope 
(Leitz, Wetzlar, Germany) 
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l 
Millipore Filter Holder 
(Millipore Corporation, Bedford , MA) 
Millipore Vacuum Pump 
(Millipore Corporation, Bedford, MA) 
uBondapak c18 
(Water Associates, Milford, MA) 
Ohaus Moisture Balance 
(Ohaus Scale Corporation, Florham Park, NJ) 
Proton Magnetic Resonance 
(Varian EM390, Palo Alto, CA) 
Roche Friabilator 
(Erweka Abrasion Tester, Erweka GmbH, Frankfurt, Germany) 
Solvent Delivery System 
(Water Associates, Milford, MA) 
Stokes Hot Air Oven 
(Stokes-Penwalt Co., East Stroudsberg, PA) 
Stokes Model F Tablet Press 
(Stokes -Penwalt Co., East Stroudsberg, PA) 
Stokes Model B2 Rotary Tablet Press 
(Stokes-Penwa lt Co., East Stroudsberg, PA ) 
Thickness Gauge 
(Va nderkamp, Vankel Industries, Chatham, CA) 
Turbula Rapid Blender 
(Wiky A. Bachoven Co., Troy, OH) 
USP Disintergration Apparatus 
(Vanderkamp, Vankel Industries , Chatham, CA) 
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USP Dissolution Apparatus 
(Vanderkamp, Vankel Industrues, Chatham, CA) 
UV Spectrophotometer 
(Hitachi 200, Perking Elmer Corporation, Norwalk, CT) 
Virtis Freeze Drier 
(Virtis Company, Gardiner, NY) 
WISP 7108 
(Wate r Associates, Milford, MA) 
X-ray Diffractometer 
(Philips Electronin Division, Mount Vernon, NY) 
Glassware and common laboratory equipment as available in 
the College of Pharmacy 
B- Methods 
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1. Studies of the interaction of beta -cyclodextrin with 
ampicillin, phenobarbitone and phenytoin. 
a. Ampicillin 
Inte raction of beta-cyclodextrin with ampicillin was assessed by studying 
the influence of the beta-cyclodextrin on the rate of hydrolysis of the 
ampicillin at 37oC in hydrochloric acid buffer of pH 2.0. The 
hydrochloric acid buffer was prepared in accordance with USP XX (128 ) . A 
known amount of ampicillin was added to each of a series of different 
molar concentrations of the beta-cyclodextrin solution. · The molar 
concentrations of ampicillin to beta-cyclodextrin were 1:1.0, 1:1.5, and 
1:2 .0. The solutions were transfered into a 100 ml volumetric flask, 
stoppered and then kept at 37oC in constant temperature bath. Samples 
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were taken at 0,3,6,9, and 12-hour time intervals. After appropriate 
dilution all samples were assayed by High Pressure Liquid Chromatogarphy 
(HPLC). This assay procedure was basically that described by Das Gupta, 
V., ~.(129). This method has been validated and is currently in 
routine use in a pharmaceutical company. Hence there was no need to 
fully validate the method again. However, the reproducibility, accuracy 
and precision were determined, these values are reported in Appendix A, 
1. 
The HPLC system consisted of a solvent delivery system, the WISP 
(Waters Intelligence Sample Processor), and a variable wavelength 
detector. The separation was performed on a 3.9mm (id) x 30cm uBondapack 
c18 (reversed phase) column. The chromatographic peaks were recorded 
using a chart recorder. The mobile phase employed in the analysis of 
ampicillin consisted of 1.4gm. / l potassium phosphate in 
acetonitrile/water (7:93 v/v). The pH was adjusted to 4.1 with 
phosphoric acid. The following chromatographic conditions were employed 
(129): flow rate= 2.0ml/min.; detector wavelength - 240nm; 0. 05 AFUs 
(Absorptions Full Scale Units); and injection volume 20 ul. 
A series of dilutions from a standard solution {3 . 15 x 10-3 M) was 
made and the peak height was determined. A calibrution curve was 
constructed by plotting the peak height of each standard dilution against 
its known concentration {Appendix A, 1). 
Beer's law states: 
A abc 
Where A absorbance or peak height 
a = absorptivity 
Eq . ( 4) 
b sample path length 
c = concentration 
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Applying Beer's law, the slope of the straight line obtained by the 
absorbance (peak height in this case) as a function of concentration is 
equivalent to the term ab in Eq. (4). 
By rearranging Eq. (4) to 
c = A/slope Eq . (5) 
The concentration of an unknown sample may be calculated. 
A graph of log concentration of the drug as a function of time was then 
plotted. The hydrolytic degradation constant (kd) and half-life (tl /2) 
with and without beta -cyclodextrin were calculated using Eqs. (6) and 
(7), respectively. 
kd = - Slope x 2.303 Eq . (6) 
tl/2 = 0.693/kd Eq . ( 7) 
The stability constant was calculated using Eq. (8) according to 
Griffiths and Bender (130). 
Eq. (8) 
Where ko and kc are the pseudo-first order rate constants for the 
degradation of uncomplexed and complexed ampicillin, respectively. kobs 
is the observed pseudo-first order rate constant, and K is the apparent 
stability constant for the complex. A plot of ( kobs - ko ) as a function 
of (kobs - ko) /beta -cyclodextrin concentration was then plotted. From 
the slope and intercept of the plot ko, kc, and K were calculated . 
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b. Phenobarbitone 
Interaction of beta-cyclodextrin with phenobarbitone was studied by 
solubility analysis. The procedure used in this study was the solubility 
method of Higuchi and Lach (131). Quantities in excess of the normal 
solubility of phenobarbitone were weighed into 20-ml vials and added to 
10-ml of aqueous solution containing various concentrations of 
beta-cyclodextrin. The vials were capped, sealed with a tape, and then 
agitated on a mechanical shaker in a constant temperature bath at 2s 0c 
until the system reached equilibrium. Two replicates were studied to 
determine the equilibrium point by assaying the samples at 17, 24, and 40 
hours as follows. At the end of each time period, contents of the vials 
were filtered through (0.45u) filter paper. Aliquot portions of the 
filtrate were properly diluted and assayed for drug content . It was 
ascertained that a 24- hour time point was sufficient to reach the 
equilibrium point. 
Based on the principles described above in section B, l; a 
calibration curve was generated (Appendix A, 2). A series of dilutions 
from a standard solution (1.72 X 10-3 M) was made and injected using the 
following chromatographic conditions which are a minor modification of 
the published method (132): flow rate = l.Sml /min.; detector wavelength-
254nm; injection volume - lOul. The same HPLC system was used as 
described in section B, 1. The mobile phase employed in the analysis of 
phenobarbitone consisted of acetonitrile, methanol, and water (20 :20:60 
v/v). A phase solubility diagram was constructed according to the method 
described by Higuchi and Connors (47). The stability constant was 
calculated from the phase solubility diagram as described in the section 
E, 1 (Eq. 1) of the introduction. 
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c. Phenytoin 
Interaction of beta-cyclodextrin with phenytoin was studied by solubility 
analysis. The solu bility was determined in a pH 7.0 using the Therell and 
Stenhagen buffer system (133 ) . The method was as described in section l, 
b, except that the drug was assayed by ultra-violet absorption at the 
wavelength of 225nm. The USP (128) value for this drug is at the 
wavelength of 258nm in water. However, at this wavelength there was no 
maximum absorption observed even with the USP standard of this drug. 
Hence, E1cm
1% was determined as in the Isola tion and Identif icati on of 
Grugs edited by Clarke (13 4). The value was found to be 27 .8 which is 
within 5% of the value reported by Clarke. Hence the reported wavelength 
(225nm) at which a maximum absorption was observed and taken as A~n a 
given medium . Based on the principles described in the method section 
8, 1, a calibration curve was generated (Appendi x A, 3) from a series of 
dilutions of a standard solution (7 .93 x 10 -SM ). It was determined that 
the cyclodextrin did not interfere with the spectrophotometric 
measurements at the concentration employed (Appe ndi x A, 4). The 
stability constant was calculated from the phase solubility diagram as 
described in the section E, 1 (Eq. 1) of the introduction to this thesis. 
2. Preparation of Drug-cyclodextrin complexes 
a. Solvent evaporation : Equimolar quantities of drugs and 
beta -cyclodextrin were added to a 50:50 mixture of water and ethanol. 
All the solids were dissolved by warming (up to 40-45oC) and stirring the 
mixture . The solution was kept at room temperature for approximately 
five days to allow complete evaporation of solvents. Moisture content 
was checked using a moisture balance. 
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b. Kneading : Equimolar quantities of drugs and beta-cyclodextrin were 
dry mixed thoroughly in a Kitchen-Aid Mixer for about 30-min. This 
mixture was kneaded with a small amount of water to make a slurry and the 
slurry was stirred well . The slurry was allowed to stand for about an 
hour and then dried at 35°c for _ approximately two-hours and screened 
through 20 mesh screen. 
c. Freeze drying : Equimolar quantities of drugs and beta-cyclodextrin 
were dissolved in water. It was necessary to add in some cases less than 
2 % of 28 % ammonium hydroxide solution to dissolve the drug completely. 
The solution was filtered through .a 100 mesh screen and then freeze dried 
using a laboratory model and as well as an industrial model freeze drier. 
The details of the freeze drying operating conditions are given in Table 
II. This freeze drying procedure was basically that described by 
Ku rozumi, ~{51 ) . 
d. Spray drying : As described in the freeze drying procedure, solutions 
were prepared and spray dried using a laboratory model spray drier. The 
details of the operating conditions are in Table III. 
3. Evaluation of the complexes 
a. Stability and solubility analysis As described in the section 8, 
of the introduction, stability and solubility studies were carried out. 
b. Infrared ( IR) spectroscopy Approximately one to two mg of drug was 
ground throughly with 80-90mg of potassium bromide (KBr) in order to give 
a thin transparent disk. Then IR spectra were measured using Perkin 
Elmer, 457, grating infrared spectrophotometer. Dr. Sandeep Gupta 
(Department of Pharmacognosy, University of Rhode Island ) supervised this 
work. 
( 
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Table II 
-Freeze drying procedure-
*1. Prefreeze the solution to be freeze dried. 
2. Turn on refrigeration before turning on vacuum pump. 
3. Do not proceed unless the temperature is between -40 tO - 50oC or 
lower. 
*4 . When the temperature is -40oC or lower, load samples. 
5. Turn vacuum pump on 
6. Operate vacuum pump ballast closed. 
7. When the desired vacuum or pressure is reached (approximately 
200u), turn the heater on. 
~*8. Ory the product between 40 to 50, till a marked decrease in 
chamber pressure or vacuum occurs. 
9. When the drying cycle is complete, turn off heater and vacu um . 
10. Slowly break the vacuum. 
11. Turn off refrigeration. 
12. Unload the product. 
-----------------------------~-- - ~-------------------------------------
*- Necessary only for laboratory freeze drier. 
~·- Difficult to monitor the product ·temperature and chamber pressure 
using a laboratory freeze drier. 
~·- These two parameters were monitored using an i ndustrial model freeze 
drier (Appendix B). 
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Table III 
Spray drying procedure 
~· Heat the unit to the desired temperature. 
e. As soon as the inlet temperature has stabilized, adjust and stabilize 
~he outlet temperature. 
p. Turn on compressed air pressure to the desired value. 
~· When the desired values have been achieved, the unit is ready for the 
spraying operation. 
5. Adjust the aspirator to regulate the spraying. 
~- Following conditions were used for the present study. 
Inlet temperature- 120 to 140oC 
Outlet temperature - 80 to 90oC 
Air pressure - 70 to 80 PSI 
Pump scale -
Aspirator scale - 10 
Heating scale - 10 
Flow indicator scale - 50 
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c. X-ray diffractometry: Specimens were placed in a shallow 
squareshaped glass holder. The holder was flat on one side, approximately 
measuring 1-5/16" x 1-3/16" x 1/8". The (28) 10- 50° diffraction angles 
were measured from the CrKalpha (2.29 A0 ) at a scanning speed of 2°/min. 
and 500 cycles per second . Dr. Thomas Rockett (Department of Chemical 
Engineering, University of Rhode Island) supervised and advised in the 
interpretation of spectra. 
d. Measurement of lattice parameters : A single crystal of the complex 
was obtained from the solvent evaporation method, and lattice parameters 
were measured using Weissenburg and Precession Photographs . Dr. Clair 
Cheer (Department of Chemistry, University of Rhode Island) supervised 
and assisted in this work. 
e. Proton magnetic resonance (PMR) spectroscopy : Approximately 10- 20mg 
of samples were dissolved in deuterium oxide solvent and filtered (a 
cotton plug was used as a filter on the pipet tip ) . The PMR spectra were 
taken using a Varian EM 390, spectrometer. Due to deuterium oxide fixed 
position, this peak was used as an internal standard in the comparision 
of the chemical shifts of the host and the guest. Dr . Nandu Bongale and 
Mr. Amarendra Mikkeleni (Deparment of Medicinal Chemistry, University of 
Rhode Island) supervised and advised in the interpretation of spectra. 
f. Differential scanning calorimetry (DSC) : Samples of approximately 
5- lOmg were placed in aluminum pans and the 120-400°c temperature range 
was measured using a Perkin Elmer Calorimeter. The heating rate was 
s0 /min . and the range was Smeal/sec. at a chart speed of 2cm/min. Dr. 
Mahendra Dedhiya (Miles Pharmaceuticals, West Heaven, CT.) supervised 
this work. 
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g. Photomicrographs : Samples were placed on a mounting slide with a 
drop or two drops of low refraction liquid. Microphotographs were taken 
on a Leitz microscope. All samples were photographed using the same 
liquid at 125x magnification . 
4. Properties of drug-cyclodextrin complexes 
a. Drug content in the freeze dried complex 
(i) Phenobarbitone beta-cyclodextrin complex 
Approximately lDOmg of a weighed sample of the complex was dissolved in 
lOOml water and lml was diluted to lOml. Three injections were made in 
triplicate, and concentration was determined by HPLC as described in the 
experimental section B, lb. 
(ii) Phenytoin beta-cyclodextrin complex 
Approximately lOOmg of a weighed sample of the complex was 
dissolved in lOOml of a pH 9. 0 buffer {Therell and Stenhagen buffer 
system) . Samples were appropriately diluted for spectrophotometric 
analysis at 225nm . The concentration of the drug was determined as 
described in the experimental section B, le . 
b. Scale-up and Yield improvement 
The freeze drying method for the preparation of the complexes was 
scaled-up from a laboratory freeze drier to an industrial model freeze 
drier. The yield was improved from 57% to more than 95%. This 
significant improvement in the yield was achieved from an open tray 
drying system to a closed tray drying system. These systems are depicted 
in Figures given the Results and Discussion of this thesis. 
c. Particle size distribution 
A nest of sieves, sizes (U. S. Standard) 20,40,60,80,100,140, and 
200, was used to measure the particle size distribution. A known amount 
57 
of sample was placed on the top screen and the sieve stack was shaken for 
30-min. on a Fisher-Wheel Sieve Shaker. The fractions in each sieve were 
collected, weighed and percent underweight values were calculated. 
d. Bulk and Tap densities 
A sample of 50 cm3 of powder was carefully introduced into .a tared 
100 cm3 graduated cylinder, weighed, tapped 100 times and measured the 
resulted volume. If V is the tapped volume in cm 3 of W grams of material 
in the cylinder, then the tapped density in gm/cm 3 is given by 
Td W/V Eq. (9) 
and bulk density 
Bd = W/50 Eq. ( 10) 
Where Td and Bd represent the tapped and bulk densities, 
respective 1 y. 
Compressibility was then determined as follows. 
% Compressibility= ( Td - Bd )/Td X 100 Eq. ( 11) 
e. Moisture content 
The moisture content of each material was determined using an Ohaus 
Moisture Balance, operating at a temperature of so0c (4 watt light) for a 
period of 30-min. The percent loss was directly read from the balance. 
f. Flowability studies 
Powder flow was determined using a recording flow meter (Fig . 6) . 
The powder flow meter design, procedure, calculations of linearity index, 
etc., were developed and described by Jordan and Rhodes (135), and 
Rudnic,~.(136). The same procedure was used in this study. 
However, the use of the flow meter was extended to study the effects of 
small mass and geometry on flow rates. This miniturization of flow 
studies was undertaken so that flow data could be obtained under 
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conditions when only small amounts of material are available. This 
makes recording powder flowmeter data useful in numerous quality control 
and in - process powder flow testing situations. Hence, a stainless steel 
hopper, a conical glass funnel, measuring 12cm (top diameter ) by 38cm 
(length) and l . 9cm (orifice diameter), and a cylidrical glass funnel, 
measuring Scm (top diameter ) by 26.Scm (l ength ) and l.5cm (o rifice 
diameter) were used to determine mass and geometry effects on flow rates . 
The delivery of a specified weight was timed, then mass flow rates were 
determined for three runs of each system. The value is only a mean flow 
rate, and the flow rate change during the flow process. A measure of 
this change is the linearity value, which was caculated as follows. 
fl : (r2 - 0.8) X 100 Eq. ( 12 ) 
Where fl is the powder flow index and r 2 is the least squares 
correlation coefficient . 
g. Compressibility studies 
Compression measurments were made using an instrumented Stokes B 
rotary press, located in the Department of Pharmaceutics of the 
University of Rhode Island. This tablet press was instrumented with four 
piezo-electric transducers and interfaced with an Apple Il e computer. 
The software to the Apple computer (developed by Mr. J. Hoblitzell) 
enabled the calculation of compression and ejection forces. In additi on, 
it also calculates mean area under the compression, ejection curves, mean 
area to height ratio for compression and standard deviation for all the 
above parameters. 
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C- Formulation of liquid dosage forms. 
1. Solution preparation and evaluation 
The compositions of two potential formulations are shown in Tab les 
IV and V. Once the dosage form was prepared, its properties were 
evaluated on daily basis to weekly, and then one month. These 
evaluations were as follows: 
a. Visual examination for clarity, such as, precipitation, crystal 
growth, change in color, odor, etc. 
b. Assay of drug content (HPLC) after samples had been stored at room 
temperature for one month. 
2. Suspension preparation and evaluation 
A final suspension formula is given in Table VI. The suspension was 
evaluated as follows . 
a. Visual examination The supernatants of the stored suspensions were 
examined for evidence of opalescene caused by very small particles, which 
are slow to settle . 
b. Sedimentation study : The sedimentation volumes were recorded in 
terms of the ultimate settled height (Hu), to the original height Ho 
(137). 
% Sediment = Hu / Ho Eq. (13) 
c. Measurement of redispersibility study : To standardize the evaluation 
of redispersibility a blender was modified (Fig . 7), such that the 
cylinder would turn through 360° at a speed of 20-22 rpm. The number of 
revolutions necessary to restore the suspension to homogen ity was 
recorded. Similar methods of evaluation have been reported in the 
literature (137). 
d. Photomicrographs As described in the experimental section B, 3g . 
Table IV 
Phenobarbitone solution formulation # 1 
Phenobarbitone beta-cyclodextrin complex * 
Glycero l 
Sorbi tol 
Simple Syrup ** 
Distilled water to make 
Dose ; 20mg/5m l 
* - Contains 20% dru g 
** - Prepared according to the USP XX 
% Ingredients 
2.0 
40 . 0 
20.0 
20. 0 
100 . 00 
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Preparation - Dissolved the complex in the mixture of glycerol , sorbito l, 
and simple syru p. Sufficient water was added to the mixture to desired 
volume . The final product was mixed well by means of a magnetic stirrer 
and filtered throug h 0. 45u filter paper. Upon filtration the product was 
flavored (Orange oil approximately three drops ) and mixed well . 
Table V 
Phenobarbitone solution fonnulation 2 
Phenobarbitpne beta-cyclodetrin comp l ex 
Glycerol 
Sorbito l 
Simple Syurp 
Distilled water to mak e 
Preparatio n As described i n Table IV. 
% Ingredie nts 
2.0 
10.0 
40.0 
20.0 
100.0 
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Table VI 
Phenytoin suspensio n fonnulation 
Phenytoin beta-cyclodextrin comp lex * 
50 : 50 mixture of water and glycero l 
quantity sufficient to make 
Dose = 100mg/5m l 
* Complex contains 20% drug . 
% Ingredients 
10.0 
100.0 
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Preparatio n : The complex was dispersed in the 50 : 50 mixture of water 
and glycerol and then made up to desired vo lume. The suspension was 
homoge nized using an hand homogenize r, flavored with Banana flavor , and 
mixed well by means of a Moto r Gene ralor Munomatic stirrer . 
c 
V..SHAPED BLENDER 
Fig. 7: A device for redispersibil i ty measurement of the 
suspens ion . 
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0- Formulation and evaluation of solid dosage form. 
Tablet formulation and preparation are given in Table VII . Tablets 
were evaluated as follows: 
a. Appea ranee 
Tablets were examined using a lOX magnifying glass for chipping 
cracking, picking or mottling of the surface as an in-process check. 
b. Weight 
The weight of each individual tablet was determined after dedusting. 
This procedure was repeated for twenty tablets. The data from the 
tablets were analyzed for sample mean and standard deviation . 
c. Thickness 
The thickness of ten tablets was determined by first dedusting, and 
then placing each of them in the jaws of a micrometer. The measurements 
were recorded and analyzed for mean value and standard deviation. 
d. Hardness 
The hardness of ten tablets was determined by placing each tablet in 
the hardness tester (Erweka), which recorded the breaking strength of the 
tablet in kilograms. This procedure was repeated and the data were 
analyzed for sample mean and standard deviation. 
e. Friability 
This test is a measure of the abrasion resistance which was 
determined by first weighing twenty tablets after dedusting, then placing 
them in a tumbling chamber for four minutes or 100 revolutions. The 
tablets were again dedusted and weighed after tumbling, and the percent 
friability was determined as follows: 
% Friability = ( Iw - Fw ) I Iw X 100 Eq. (14) 
Where Iw and Fw represent the initial and final weights, respectively. 
Table VII 
Phenytoin tablet fonnulation 
Phenytoin beta-cyclodextrin complex * 
Sodium starch glycolate 
Magnesium stearate 
Microcrystalline cellulose to make 
pose = 50mg/tablet 
~ - Contains 20% drug 
% Ingredients 
80.00 
1.50 
0.75 
100 . 00 
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Preparati on : Preweighed complex and sodium starch glycolate (0. 75 %) were 
~horoughly mixed for fifteen minutes in a Kitchen Aid Mixer, and wetted 
~sing water as a gra nulating agent. The wet mass was seived (10 #) and 
~ried at 40oC to approximately a moisture level of 5% as detennined by a 
~oisture balance. Dried mass was reseived (20 #) to produce unifonn 
granules, then mixed for ten minutes with the remaining (0.75%) sodium 
starch glycolate and microcrystal line cellulose (app. 18%). The 
~agnesium stearate was mixed in a Turbula Rapid Blender for three minute~ 
~ith the tablet matrices and tablets were compressed. Punch diameter wa~ 
approximately 0.95cm and target weight was 312.50mg. 
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f. Ease of manufacturing 
The noise and vibration from the tablet press were carefully 
monitored subjectively to identify any problems in manufacturing tablets. 
g. Disintegration 
Tablet disintegratio n was tested using the USP apparatus, as 
described in the U. S. Pharmacoepia (128). The time needed for all the 
palpable fragments to pass through the screen at the bottom of the cage 
was detected visually and was recorded. Six tablets were used in each 
test, and mean and standard deviations were calculated . 
h. Dissolution 
When a drug was to be measured for rate and extent of dissolution, a 
sample of the lot of drug to be used was placed in various concentrations 
in a spectrophotometer to measure the max for that particular drug. 
Once this value was determined, the spectrophotometer was set at that 
wavelength, and each sample was analyzed for absorbance. The result was 
recorded on a Beer's plot (as described in the method section B, 1) and 
correlation between absorbance and concentration was recorded. The 
monograph, as it appeared in the USP (128) was used as a reference for 
determining the dissolution medium for the test . In addition, 
dissolution was determined in acidic (pH 2.2) and basic media (pH 7.4). 
The requried acidic and basic media were prepared in accordance with the 
USP (128). A sample of three and six tablets wer~ · used for each system. 
The samples at specified time intervals were withdrawn and diluted with 
dissolution medium to read the absorbance between 0.1 and 0.7. Because 
of the rather limited aqueous solubility of the phenytoin, samples of the 
tablets were carefully cut in to two halves and based on weighed portions 
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of the tablets, dissloved drug concentrations were determined.The 
concentations were determined from the Beer's plot (Appendix A, 5). 
III Results and Discussion 
The results and discussion are organ iz ed i nto the following main 
sections. 
A. Phys ico- chemical properties of complexe s 
a. Stability 
b. Solubility 
c. X-ray diffractometry 
d. Measurement of lattice parameters 
e. Differential scanning calorimetry 
f. Infrared spectroscopy 
g. Proton magnetic resonance spectroscopy 
h. Photomicrographs 
B. Preparation of the complexes 
a. Solvent evaporati on 
b. Kneading 
c. Spray drying 
d. Freeze drying 
C. Preparation and evaluation of dosage forms 
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A. Physico-chemical properties 
a. Stability 
Complex formation of ampicillin with beta-cyclodextrin was studied 
using different molar concentrations of the beta -cyclodextrin with an 
ampicillin solution. Figure 8. depicts the results of this study. It is 
readily evident that the beta -cyclodextrin has a stabilizing effect on 
the ampicillin hydrolysis rate. The disappearance of ampicillin displayed 
a pseudo-first order kinetic behavior in the solutions with or without 
beta-cyclodextrin From this figure and using equations six and seven 
the observed pseudo- first order rate constants and half-lives were 
calculated. The results are repo r ted in Table {VIII) . An analysis of 
variance {ANOVA) was used to evaluate any statistical significance among 
the treatments. There was a significant difference (.£.=0. 05) between the 
treatments with 1:0 .0 and 1:1.0 molar concentrations of ampicillin to 
beta-cyclodextrin. Furthermore, due to the single replicate nature of 
the data and the constant time period between observations it was deemed 
more appropriate to evaluate the colinearity of the degradation curves 
presented in Fig . 8. This analysis detected a significant difference {-<. 
= 0.05) between the slopes associated with the treatments using ratios of 
1:0.0 and 1:1 . 0 of ampicillin to betacyclodextrin. In order to determine 
the optimal ratio of beta-cyclodextrin to ampicillin, a graph was 
constructed by plotting the observed degradation rate constants as a 
function of the beta-cyclodextrin concentration. As seen in Fig. 9, the 
observed degradation rate constant asymptotically approaches a minimal 
value as the beta-cyclodextrin concentration is increased. This 
saturation behavior is a characteristic of reactions which proceed 
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MOLAR RAT10 OF A:·IP. : SETA- CO 
9 
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12 
Fig'. 8: Hydrolysis of ampici llin with differentrrolar concentrations 
of beta-cyclodextrin at pH 2.0 and 37°C 
* Each point represents an average of three determinations 
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Table VIII 
Degradation constants and Half- lives of ampicillin with different molar 
concentrations of beta-cyclodextrin at pH 2.0 and 37oc 
Mola r rat i o 
of 
Amp . and Beta-CD 
1.0:0 . 0 0.052 1.3. 30 
1.0:1.0 0.018 38.50 
1.0:1.5 0.012 57.75 
1.0:2.0 O. Oll 63.00 
t 
kd : The degradation constant of ampicillin without beta-cyclodextrin / 
kd' : The degradation constant of ampicillin with beta-cyclodextrin 
t 112 : The half-life of ampici llin without beta-cyclodextrin 
t 112 • : The half- life of amp1c1llin with beta - cyclodextrin 
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Fig. 9 Effect of beta -cyclodextrin concentrat i on on the ps2~ao -
first order rate constant for the hydrolysis of ampi -
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through a complex prior to the rate- determining step and may be 
accolTITiodated by the mechanisim illustrated in the following scheme (130) . 
Amp. + Beta - CD 
I 
l<o : 
I 
k Amp. B~ta-CD 
' I 
I 
; "'~ 
I 
I 
~ Degraded products ----1 
Where Amp., Beta-CD, and Am p. Beta-CD, represent ampicillin, 
beta-cyclo-dextrin and the inclusion complex of ampicillin with the 
beta-cyclodextrin, respectively. The pseudo-first order rate constants 
fa~ the deg radati on of uncomplexed and complexed ampicillin are k0 and kc 
and K is the apparent stability constant for the complex. In Fig. 10 the 
rate constants of Fig. 9 are plotted according to Eq. (8). 
For example: 
kobs - k0 = - (kobs - k0 )/K(Beta - CD) + kc - k0 
A plot of kobs - k0 as a function of (kobs - k0 )/ beta-cyclodextrin 
is shown in Fig. 8. From the slope and intercept of the plot k0 , kc, and 
K were obtained and they are reported in Table (IX) . It is clear from 
the data that the complex degrades nine times slower than the drug 
itself, which is an indicative of a fairly stable complex. In addition 
the calculated stability constant (458.46M- 1) is also characteristic of 
the extent of complex formation and may be suitable for practical 
application, since too labile complexes result in premature release of 
the drug and too stable complexes result in a retarded or incomplete 
release of the drug. It has been reported (23) that only those complexes 
with stability constant between 200 - 5000 seem to be suitable for 
practical applications. The author of this thesis found no literature 
data available on the ampicillin beta -cyclodextrin complex with which to 
compare the results from this study. 
-2 
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(kobs - k0 ) I (BETA-CO ) M-
1HR - l 
Fig. 10 : Plot of th e rate data according to Eq. d 
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Table IX 
Degradation constants and stability constant of the inclusion complex of 
ampicillin-beta -cyclodextrin 
Deg radation constant {ko) of the drug . 5. 00 x 10-2hr- l 
Degradation constant {kc) of the complex 0.55 x l0 - 2hr- l 
Stability con~tant (K) of the complex 458.46M-l 
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b. Solubility 
The solubility method of Higuchi and Lach (131) was used to study 
the complex formation of phenobarbitone and phenytoin . Interactions of 
these two drugs were studied by solubility analysis. A phase solubility 
diagram of phenobarbitone was constructed according to the method 
described by Higuchi and Connors (47) and is depicted in Fig. 11. There 
was a five-fold increase in the solubility of phenobarbitone due to 
complex formation. According to the authors of the phase solubility 
techniques, if a plot of the total molar concentration of substrate as a 
functio n of the total molar concentration of ligand and the complex is of 
a 1:1 type then a straight line with a positive slope will result. Thus, 
from such plots the stability constant (K) can be calculated using Eq. 1 
as foll OWS: 
K = Slope/S0 (1-Slope) 
Where S
0 
is the solubility of the substrate (phenobarbitone ) in t he 
absence of the ligand (beta -cyclodextrin) . In other words, S0 is the 
intercept as shown in Fig. 9, and using the slope from this figure, the 
stability constant can be obtained. However, if the slope is greater 
than unity, as in this case (Fig. 9), it becomes impossib l e to calculate 
the stability constant using the above equation. Hence, the derivation 
of the above equation was reexamined, and it was modified to calculate an 
approximate apparent stability constant as follows. 
Higuchi and Connors derived the above Eq. l fr om the fol lowing 
equation. 
(mKSm Lt )/( l+ KSm ) +S 
0 0 0 Eq. ( 15 ) 
{ 
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Fig . 11 : Solubility of phencrbarbitone as a functiorr- uf Let<: 
cyclodextrin in water ot 2s0c. 
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Where St and Lt represent the total molar concentration of substrate 
and ligand, respectively . S0 is as defined before and m is the 
stoichiometric coefficient . 
A pl ot of St as a fu nction of Lt for the formation of a soluble 
complex should therefo re yield a straight line. The intercept is equal 
to S
0 
and the slope is given by: 
Slope = mKS
0
m/ l+ KS
0
m Eq. (16) 
If mis known or for simplicity is equal to 1, then equation 16 
becomes: 
K = Slope /S
0
(1 - Slope) 
Howeve r, as pointed out earlier, if the slope is greater than unity, 
the assumption of a 1:1 complex alone is ma nifesting untenable, and the 
calculation of the stability constant according to the above equation is 
impossible. In such cases, according to the authors of the more general 
expression (Eq. 15), it may be used by assigning a value tom. 
In order to determine the value of m, the complex was isolated 
(preparation is discussed in Section JIB, 2) and assayed. The results 
are reported in Table (X). Based on the percent drug content in the 
complex, the value of mis calculated as follows . 
The molecular weight of phenobarbitone is 232gm/mole and that of the 
beta-cyclodextrin is 1135gm/mole . Hence, the number of moles in 20% of 
the drug is equal to 8.62 x 10- 2 and that of beta -cyclodextrin is equal 
to 7.05 x 10-2. The ratio of substrate to ligand gives 1.22, indicating 
that the complex formula is s1. 2L. Based on these calculations a value 
form was obtained and substituted into the equation(16 ) . 
Slope = mKS0m/ l+KS0 
By rearranging Eq . 16 to 
Eq. (16) 
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Table X 
Drug content in the freeze dried phenobarbitone beta-cyclodextrin 
complex. 
Batch No 
2 
Batch size (in liters) 
10 
10 
% Drug content 
20.00 
19.68 
K = Slope/ S0m(m - Sl ope ) 
When m = 1. 2 Eq . (17) results to 
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Eq. ( 17 ) 
K =Slope I s0
1
·
2(1.2 - Slope ) Eq. (18 ) 
The calculated apparent stability constant is 4.54 x 103M-l by using the 
slope and intercept values from Fig . 9. This value is close to the va l ue 
(3.60 x 103M- 1) obtained by Thoma and Stewart (9). Although the 
stability constant value obtained by Thoma and Stewart is cl ose t o the 
value obtained in the present study, there is a discrepancy. This 
discrepancy can be explained as follows . Firstly, the reported stability 
constant value by Thoma and Stewart was from the interaction study 
carried out at 30°c, whereas, the present study was carried out at 2s 0c. 
Hence there is a temperature effect on the stability constant . Second ly , 
unless a solid complex is isolated and its stoichiometry analyzed, 
calculation of the exact stability constant may lead to an approximati on. 
It is the opinion of the author of this thesis that Thoma and Stewart did 
not isolate the complex to detennine the stoichiometry; hence there is a 
discrepancy in the stability constant values. Further, Higuchi and 
Connors (47) also pointed out in their phase solubility techniques that 
the stoichiometry and the equilibrium constants may be ambiguous 
quantities . Hence (according to them), whenever there is an ambiguity or 
conflicting results, a solid complex should be isolated and its 
stoichiometry analyzed and compared with a graphical estimate of the 
stoichiometric ratio. Thus, the phenobarbitone beta-cycl odextrin comp l ex 
may be a molecular ratio of 1. 2:1.0, rather 1:1. 
The results of the interaction of phenytoin with 
beta-cyclodextrin are depicted in Fig . 12. There was an el even-fold 
increase in the solubility of phenytoin due to the complex formati on. 
12 
10 
" 80 
z 
0 
I-
< 
"" I-z 
U-1 
:::< 
0 60 u 
z 
0 
I-
>-
"" !::!
a: 40 
20 
82 
0 
R2 = 0.986 
Sl ope = 6. 75 x 102 
0 lnterceot = 9.45 x l05e< 
n = 2 
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0 6 9 12 
BETA- CYCLODESTRI N CONCEIHRA TTOH x 103M 
Fig. 12: Solubility of phenytoin as a function of beta-
cyclodextrin in pH 7.0 buffer at 25°c. 
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Uekama (117) reported the solubilities of several drugs in water both in 
the presence and in the absence of beta-cyclodextrin. Among the reported 
drugs is phenytoin . These results are reported in Table (XI) along with 
the results of the present study . Although the results are very close to 
each other there is a slight discrepancy. This discrepancy may be due to 
the concentration of cyclodextrin in the solubility study. Since Uekama 
did not use a saturated solution of beta -cyclodextrin (Table XI) , there 
is a slight decrease in the total solubility of phenytoin . However, he 
obtained a higher solubility in the absence of cyclodextrin; hence, it 
may be said that both results are comparable. Uekama reported neither 
the range of the cyclodextrin concentration used nor the stability 
constant of the complex. 
A phase solubility diagram was constructed from the solubility data 
of phenytoin and is shown in Fig . 12. From this phase diagram, and using 
Eq. 1, the stability constant {766M- 1) of the complex was obtained. As 
shown in Fig. 12, in this interaction study, the slope is less than unity 
and hence there was no need to determine a value for m (Eq . 16) to 
calculate the stability constant. However, a solid complex was isolated 
(preparation is described in Section IIB, 2) and the drug content in the 
complex was analyzed by a spectrophotometric method. The results of the 
drug content in the complex are reported in Table XII . Based on the drug 
content in the complex, the ratio of the substrate concentration to the 
ligand concentration {ob tained as described earlier) gave a value of 
1.05 . This value is an indication of the complex with a molecular ratio 
of 1:1. 
Lach and Cohen {40) studied the interaction of nineteen compounds 
with alpha and beta-cyclodextrin. The data in their study indicate that 
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Table XI 
Comparis ion of phenytoin solubility data with t he r eport ed literature 
data. 
~olubi lity at 25oc Solubility in beta-cd solution Sc / So 
in water (ug/ml), S0 (ug/ml ) , 5c 
1*28 282 10 .00 
1**25 277 11.00 
-----------------------------------------------------------------------~ 
* Reported values (1 17) 
** Detennined vlues by the author of this thesis in pH 7.00 buffer. 
Concentration of the bet-cyclodextrin used: 
* 13 x l0-3M 
** 15 X l0-3M 
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Table XII 
Drug content in the freeze dri ed phenytoin beta-cycl odextrin complex 
~atch No Batch size (in liters) 
* 
8 
10 
* - Prepared by using a laboratory freeze drie r. 
% Drug content 
18.88 
18 . 30 
18 . 90 
,-
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those drugs which are least soluble in water show the greatest increase 
in solubility as a function of quantity of cyclodextrin present. In 
addition, in their study, the drugs which are low in molecular weight and 
more soluble show the highest slopes. Similar results are shown in Table 
XIII, phenobarbitone shows the highest slope compared to phenytoin, since 
phenobarbitone is more soluble than phenytoin . However, increase in 
solubility of phenytoin relative to its initial solubility is eleven-fold 
compared to only a five - fold increase in phenobarbitone solubility. This 
increase in solubility, especially for phenytoin, has a considerable 
potential in the development of suitable dosage forms. The extent of 
complex formation (as evidenced by the stability constant) of 
phenobarbitone is greater than that of phenytoin. This stronger 
interaction of phenobarbitone may be due to the size of the molecule. 
Since the size of the phenobarbitone molecule is smaller than the 
phenytoin molecule (Table XIII), smaller molecules may fit well into the 
beta-cyclodextrin cavity to form a more stable complex. Cohen and Lach 
(36) also felt that geometrical rather than chemical factors are decisive 
in determining the extent of complex formation. 
c. X-ray diffractometry 
The X-ray diffractometer allows us to examine the atomic arrangement 
of a material, giving information on crystal geometry and structure . It 
has been reported (49, 50) that an inclusion complex can be detected 
quickly and directly by the X-ray methods. As per these reported 
studies, a true inclusion complex may exist if the diffraction pattern 
does not correspond to those of pure components. 
Figures 13 and 14 show the X-ray diffraction patterns of phenytoin 
and the beta-cyclodextrin. As shown in the Fig. 13c, the diffraction 
\ 
87 
Table XIII 
Slopes of intera ction isotherms, solubility data and stab ility constants . 
Drug Stability 
constant K(M - 1) 
r Phenobarbitone 4. 53 X io3 
* * Phenytoi n 766 
Sl ope 
1. 08 
0.0675 
* Solubi l ity = l. Omg/m l in wate r at 25oC ( 134) . 
**Solubility = 7.0ug/ml in water at 24oC (138) . 
C' 
Increase in M. wt . 
solub ility 
5-fold 232 
11- fol d 25 2 
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a 
30 20 10 
2 9 (0) 
Fig. 13: Powder X-ray diffraction patterns 
Key: a- Phenytoin, b- Beta-cyclodextrin, c-Freeze dri ed 
complex, d- Phyxical mixture of a and b. 
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c 
30 20 10 
2 a (o) 
Fig. 14: Powde r X-ray diffraction pa tterns 
Key: a- Freeze dried phenytoin, b- freeze dried beta-
cyclodextrin, c- Physica l mixtu re of a and b, 
d- Kneaded complex. e- So 1 vent evaporated come 1 ex . 
f- Spray dried complex. 
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pattern of the freeze dried material is different from that of the pure 
components and their physical mixture. The diffraction pattern of the 
physical mixture was found to be a simple superimposition of those of the 
components. The X-ray diffraction pattern shown in the Fig. 14b, 
i ndicates that the beta-cyclodextrin, which was originally in a 
crystalline fonn (Fig . 13b), is transfonned to an amorphous state after 
freeze drying. Similarly, the phenytoin was originally in a crystalline 
fonn; which did not transfonn to an amorphous state after freeze drying 
of phenytoin alone (Fig. 14a); however, the complex prepared by the 
freeze drying method was transfonned to an amorphous state and indicated 
t he fonnation of a new solid phase . This new solid phase is clearly 
shown in Fi g. 13c, around 28°. The complex prepared by the other 
methods, such as kneading, solvent evapo rati on , etc., did not transfonn 
into an amorphous state as evidenced by the diffraction patterns (Fig. 
14d and 14e). However, unlike the physical mixture, the diffraction 
patterns are not a simple superimposition of the pure components. The 
diffraction patterns of the complexes differed from those of the physical 
mixture (diffused diffraction patterns), thus i nd icating the existence of 
the complex as a separate molecular species . 
Seo,~(88), studied the X-ray diffraction patterns of 
spironolactone beta-cyclodextrin systems. In their studies they also 
observed that, the diffraction patterns of the physical mixtures were 
simply the superimposition of each component pattern, while those of 
complexes were apparently different. Similarly, Uekama, ~ (87) , 
also interpreted the powder X- ray diffraction patterns of acetohexamide 
beta-cyclodextrin complex and their physical mixture. In addition, 
Tokumura, ~ {166), also reported the X-ray diffraction patterns of 
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cinnarizine beta-cyclodextrin complex and their physical mixture . In 
their results also, the diffraction pattern of the physical mixture was 
found to be a simple superimposition of those of the components , and that 
of the complex was apparently different. 
Figures 15 and 16 show the diffraction patterns of phenobarbitone 
the complex. The X-ray diffraction patterns shown in Fig. 15b indicate 
that , like phenytoin, phenobarbitone also retains its crystalline form 
even after freeze drying. However, the phenobarbitone beta-cyclodextrin 
complex prepared by the freeze drying method is completely transformed to 
an amorphous state (Fig . 15c). The physical mixture pattern is a simple 
superimposition of the pure components (Fig . 16c). Hence, it is clear 
that the diffraction patterns of the complex differed from that of the 
physical mixtures, indicating the existence of the complex as a separate 
molecular species. 
d. Measurement of lattice parameters 
It was possible to obtain a single crystal of the phenytoin 
beta-cyclodextrin complex by the solvent evaporation method. The results 
are reported in Table (XIV) . As shown in the Table, one of the axial 
lengths (A) has almost doubled, indicating a different molecular order . 
This new molecular order may be due to inclusion complexation of 
phenytoin with the beta-cyclodextrin. Based on the X-ra y resluts and 
solubility characteristics, it is possible by inclusion complexation that 
the axial length (A) may have changed. However, in order to reach a 
definitive conclusion, this question is deferred for further study. 
Since, the author of this thesis could find no data reported in the 
literature on the measurement of the lattice paramete rs of inclusion 
complexes. 
30 
Fig. 15: 
Key : 
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a 
b 
d 
0 10 
2 a (o) 
Powder X-ray diffraction patterns 
a- Freeze dried beta-cyclodextrin, b- Freeze dried 
phenibarbitone, c- Freeze dried complex, d- Spray 
dried complex. 
30 
Fig. 16: 
Key: 
93 
a 
20 10 
e (o) 
Powder X-ra y diffraction patterns 
a- Phenoba rbi tone, b- Freeze dr ied phenoba rbi tone, 
c - Freeze dried beta - cyclodextrin, 
d- Physi cal mixture of b ana c. 
Axial length 
* l 
** 2 
Table XIV 
Lattice parameters data 
A 
21.29 
42. lB 
B 
10.33 
11.04 
*- Reported values of beta - cyclodextrin unit cell dimensions . 
Carbhohydrate Research, 99, 103 (1962) 
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c 
15.10 
15 .05 
**- Measured values of phenytoin beta-cyclodextrin complex prepared by 
the solvent evaporation method. 
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e. Differential scanning calorimetry (DSC) 
Cyclodextrins complex formation may be proved by DSC. Figure 17 
shows the DSC curves of freeze dried phenytoin and the freeze dried 
complex. In Figs . 17 and 18 the freeze dried phenytoin and 
beta-cyclodextrin gave an endothermic peak around 29S°C {568°K) , which 
corresponds to the melting points of the phenytoin and beta-cyclodextrin. 
The freeze dried complex and the physical mixture {Figs . 17 and 18) also 
gave an endothermic peak around the same temperature (Fig . 18). However, 
the pattern of the freeze dr ied complex thermogram is clearly different · 
from that of the phys i cal mixtu re. These thermograms suggest that there 
is some interaction in the freeze dried complex but not in the physical 
mixture. Because of the very narrow range of the melting points of the 
phenytoin and beta-cyclodextrin (Table XV), it was not possible to 
elucidate clearly the presence of the inclusion complex . In order to 
demonstrate the absence of the inclusion complex in the physica l mixture, 
DSC cu rves of phenobarbitone and the beta -cyclodextrin were depicted as 
shown in Figs. 19 and 20 . Since there is clearly a wide range of 
difference in melting points (Table XV), it was possible to distinguish 
the presence and absence of the true inclusion complex by observing the 
endothermic peaks of the two different molecules . This phenomenon is 
elucidated in the Fig . 20 . These thermograms strongly suggest the 
presence of the inclusion complex in the freeze dried material but not in 
the physical mixture. 
Similarly, Kurozumi, ~ {5 1) have found that freeze dried 
mefenamic acid gives at 232oC an endothermic peak; its mechanical mixture 
also gives the same peak at the same temperature; but the complex 
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Table XV 
Melting points data on phenytoin, phenobarbitone and beta-cyclodextrin. 
Drug Melting Point (°C) 
Phenytoin 295 - 298 
Phenoba rb itone 174 - 177 
Beta-cyclodextrin 300 - 310 
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prepared by the freeze drying method does not. Hence, this behavior is 
usually a characteristic of inclusion complexes. 
f. Infrared (IR) spectroscopy 
Figures 21 and 22 show the IR spectra of the phenytoin and 
beta -cyclodextrin. The complex formation may be proved by IR because 
bands due to the included part of the guest molecule are generally 
shifted or their intensities are altered. However, the results shown in 
Figs. 21 and 22 can not be readily interpreted in an unambiguous manner 
since the physical mixture and the freeze dried complex show by and large 
similar patterns. This similarity in the patterns of freeze dried 
complex and the physical mixture can be explained as follows . 
(i) In general, the mass of the guest molecule in a complex does not 
exceed more than 25% (8) of the mass of the complex. 
(ii) This phenytoin beta-cyclodextrin complex contains around 20% drug in 
the complex (Table XII). 
For IR spectra , one or two mg of sample is used with 80- 90 mg of 
potassium bromide. Hence, in the one or two mg complex, the active drug 
content is only a few micrograms . Therefore, if any bands are altered 
due to the included part of the guest molecules, these alterations may 
possibly obscure the spectrum of the host. Similar exp la inations are 
reported in the literature (8) in the study of pyrethrin-cycl odextrin 
complexes. 
g. Proton magnetic resonance (PMR) spectroscopy 
Recently, nuclear magnetic resonance (NMR ) methods have contributed 
greatly to the understanding of the cyclodextrin interaction with 
different guest molecules. The PMR investigation of the complexes of 
cyclodextrins was technically difficult due to the low solubility of the 
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complexes in deuterium oxide. In organic solvents, such as 
dimethylsulfoxide, chloroform, etc., complex can be di·ssolved; however it 
has been reported (8) that the complex decomposes, and the cyclodextrin 
complex of the solvent is formed. This is posible since in the complex 
formation the nonpolar part of the guest molecule penetrates into the 
nonpolar cyclodextrin cavity, thereby establishing an energetically 
favorable nonpolar-nonpolar interaction . When an organic solvent is used 
to dissolve the complex, if the solvent is more polar than the included 
guest molecule, then a complex with the organic solvent will be formed. 
In this study, since the phenytoin beta-cyclodextrin complex did not 
dissolve in the deuterium oxide, it was very diffcult to show the complex 
formation in the liquid phase . However, the phenobarbitone complex 
readily dissolved in the deuterium oxide, and the results are shown in 
Fig. 23 . The large peak at approximately 4.6ppm is common to both 
spectra due to small amounts of deuterium hydroxide and water as 
impurities. All the peaks observed in the Fig. 23a, are those of the 
beta-cyclodextrin . The deuterium oxide peak is fixed in both spectra; 
this peak was used as an internal standard for the comparison of the 
chemical shift observations. From the spectra of both the 
beta-cyclodextrin and the complex, it is clear that all of the protons of 
the complex located in the internal cavity of the beta-cyclodextrin are 
experiencing a shielding effect; hence signals are shifted upfield (Fig . 
23b). These spectra strongly suggest the presence of the complex in the 
liquid phase. 
Demarco and Thakkar (52) reported ~hat the protons l ocated in the 
interior cavity of the beta-cyclodextrin (C - 3-H, and C-5-H) will be 
considerably shielded by the guest molecule; hence the signals will be 
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shifted upfield. Whereas, the protons on the outer surface (C-2-H, 
C-4-H, and C-6-H) will not be affected by the guest molecule; hence the 
signals of those protons will remain unchanged. In addition, Frank and 
Cho (32) also observed similar results in the study of the complexing 
behavior of dinoprostone with beta-cyclodextrin in water. 
h. Photomicrographs 
Figures 24, 25 and 26 show the morphology of recrystallized 
beta-cyclodextrin, phenytoin, and phenobarbitone before and after freeze 
drying . All the photomicrographs were taken at the same magnification 
(125x) . As shown in the Fig. 24a, the beta-cyclodextrin is a crysatlline 
material, however after freeze drying it has completely transfonTied into 
an amorphous state. This amorphous state is also confinTied in the X-ray 
analysis (Fig. 14b). Whereas phenytoin and phenobarbitone (Figs. 25b and 
26b) as seen i n the X-ray analysis (Figs . 14a, and 15b) did not 
transfonTI into an amorphous state, the complex prepared by the freeze 
drying method of these two drugs as shown in Figs . 27b, and 28b, are 
completely transfonTied into an amorphous state. This was also previously 
observed in the X-ray analysis (Figs . 13c, and 15c). The complex 
prepared by various methods are shown in Figs. 27a, 28a, and 29. It is 
very diffcult to prove in an unambiguous manner the fonTiation of an 
inclusion complex in these photomicrographs; it can be readily shown in 
Fig. 29b that, some kind of interaction has taken place in the complex 
prepared by the solvent evaporation method. As previously discussed, a 
single crystal isolated from this preparat ion was taken for lattice 
parameters measurement and showed an increase in one of the axial length. 
The results are reported in the Table (XIV) . Based on this 
photomicrograph, the lattice parameters data, and also from the X-ray 
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Fig . 24a: RECRYSTALLIZED BETA- CYCLODEXTRHI AT l 25x. 
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Fig. 24b: FREEZE DRIED BETA- CYCLODEXTRrn AT l25x. 
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Fig. 25a: PHENYTO!N AT 125x . 
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( 
Fig. 26a: PhENOBARBITONE AT 125x. 
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Fig. 27b : FREEZE DRIED PHENYTDIN COM PLEX AT 12Sx. 
Fig. 28a: SPRAY DRIED PHENDBARBITONE COM PLEX AT 12Sx. 
Fig. 28b: FREEZE DRIED PHENOBARB rTON E COMPLEX AT 12Sx . 
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Fig. 29b: SOLVENT EVAPORATED PHENYTOIN COMPLEX AT 125x. 
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diffractogram, it is conceivable that inclusion complex may be present in 
the solvent evaporated material. 
B. Preparation of the complexes 
a. Solvent evaporation 
Solvent evaporation is a simple method however, it is a costly and 
time consuming procedure because: 
(i) . The solvent of a small batch size of 200ml requires at least 10-12 
days to evaporate at room temperature. 
(ii) . The solvent is 50% ethanol, which is expensive and without a 
solvent recovery system this process may not be economically feasible. 
A phenytoin beta-cyclodextrin complex was prepared by this procedure 
with a satisfactory yield of 95%. The final end product was in a 
crystalline form. As discussed in Section !!IA, d., th e measurement of 
lattice parameters showed some interaction with the beta - cyclodextrin. 
However, in order to collect a reasonable quantity of material to begin 
formulation work, it would take several months' time to collect a 
workable amount of material. Further, even in the lite rature this method 
of preparation of inclusion compounds has not been explored. 
b. Kneading 
In the preparati on of inclusion compounds the most common techinque 
is to stir or shake an aqueous solution of cyclodextrin with a guest 
molecule or its solution. In aqueous solution the apolar cyclodextrin 
cavity is occupied by water molecules that are in an energetically 
unfavorable state (polar - apolar repulsion) and are, therefore readily 
replaced by an appropriate guest molecule that is less polar than water 
(Fig. 4). In this kneading process the cyclodextrin is not dissolved, it 
is kneaded with a small amo un t of water to make a slurry, and then guest 
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components are added to the slurry of cyclodextrin. Since neither the 
guest nor host molecules are dispersed at a molecular level, it is 
difficult to conceive the formation of inclusion compounds in this 
process. However, this method of preparation has been reported in the 
literature (8). 
A phenytoin-beta-cyclodextrin complex was prepared by this method 
with a satisfactory yield of 92% . Only the X-ray-analysis (Fig. 14 ) , 
showed ambiguously the presence of the inclusion complex as a separate 
molecular species. Thus, it is interesting to see the effect of kneaded 
complex on formulations. 
c . Spray drying 
Figs. 27a and 28a show the morphology of spray dried phenytoin and 
phenobarbitone complex with beta -cyclodextrin . It appears from the 
photomicrographs that the complex may be a physical mixture of the pure 
components (Figs. 24a, 25a and 26a). These types of results may be 
conceivable from the spray drying process as follows. 
During the spray drying process the surface liquid is quickly 
evaporated and a tough shell of solids may form in its place. As drying 
proceeds, the liquid in the interior of the droplet must diffuse through 
this shell; however, the diffusion of the liquid occurs at a much slower 
rate than does the transfer of heat through the shell to the interior of 
the droplet. The resultant build-up of heat causes the liquid below the 
shell to evaporate at a far greater rate than it can diffuse to the 
surface. The internal pressure causes the droplet to swell; and if the 
shell is nonelastic, it ruptures, producing either fragments or ruptured 
hollow spheres and perhaps some intact spheres . Therefore, when the 
cyclodextrin solution with the drug is sprayed, if the shell is 
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nonelastic, it may rupture producing fragments of drug and cyclodextrin 
or there may be fragments of both species together. Hence, if the shells 
of cyclodextrin solids are nonelastic it may not be possible to produce 
an intact cyclodextrin species containing drug molecules. 
As shown in Figs. 14 and 15, only the X-ray analysis showed some 
kind of interaction with beta-cyclodextrin rather than a physical mixture 
of the pure components. The photomicrographic evaluations are highly 
subjective; therefore based on the X-ray analysis, it is felt that the 
inclusion complex exists as a separate molecular species. 
However, there was only a 10% yield of the complex prepared by this 
method. The low yield is due to the poor design of the equipment rather 
than technique, because of the following reasons: 
(i). 
(ii). 
The solution was sprayed as fine droplets into a moving stream of 
hot air, where they did not evaporate rapidly before reaching 
the wall of the drying chamber. 
The resultant build-up of liquid droplets on the wall of the 
drying 
yield. 
chamber did not dry into a fine powder to give a good 
(iii). The temperature of the system was fluctuating constantly during 
the spraying process. 
(iv) The peristaltic feed pump was not functioning properly. 
Therefore, because of the unsatisfactory yield,, this method was not 
explored further. 
d. Freeze-drying 
Among the various methods of preparing the inclusion complexes, this 
method was satisfactory at a laboratory level. However, the ampicillin 
inclusion compound could not be prepared by this method since it has been 
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(114) reported that the rate of decomposition of the ampicillin increases 
upon freezing. Savello and Shangraw (139) showed that for a 1% sodium 
ampicillin solution in 5% dextrose, the percentage of degradation at four 
hours is approximately 14% at -20°c, compared to 10% at s0c. Therefore, 
only phenytoin and phenobarbitone beta-cyclodextrin complexes were 
prepared firstly by using a laboratory freeze drier. 
As shown in Fig. 13c, the phenytoin beta-cyclodextrin complex 
prepared by the freeze drying method strongly suggested the presence of 
inclusion complex as a separate molecular species . In addition the OSC 
thermograms (Fig. 17) also suggested that the freeze dried complex is not 
a physical mixture. Similarly, the DSC thermograms of the phenobarbitone 
complex (Figs . 19 and 20) and the NMR spectra (Fig. 23) strongly 
indicated the presence of the inclusion complex in solid phase as well as 
in liquid phase. 
Although there are different methods of preparing the inclusion 
complexes, they are not suitable at the pilot scale or manufacturing 
level. Kurozumi ~ (51) prepared the inclusion compounds of 
non-steroidal antiinflammatory and other slightly soluble drugs with 
alpha and beta -cyclodextrins. They reported that the freeze-drying 
method was successful in obtaining the inclusion compounds of all the 
test drugs. However, they did not describe how such inclusion compounds 
can be produced at the pilot scale or manufacturing level. Similarly 
Lach and Cohen (40) studied the interaction of nineteen compounds with 
cyclodextrins, but they did not report how to harvest these inclusion 
compounds. 
In the present study, preparation of the inclusion compounds using 
the freeze drying method is expanded from a laboratory freeze drier to an 
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industrial level freeze-drier. Since the laboratory freeze drier was not 
capable of handling more than a liter per batch, the batch size was 
limited to one liter. The total time required to comp lete the batch was 
4-5 days. Although theoretically the yield per batch (with 2% solids) 
was 20 grams, the experimental yield was only 18 grams. Therefore, in 
order to begin formulation work by using the laboratory freeze dryer it 
would take months to collect a reasonable quantity of material. Hence, 
the success of a new drug or complex for dosage forms formulation work is 
dependent upon scale-up evaluation from laboratory procedure to routine 
production operations. 
With this in mind two phenytoin beta-cyclodextrin complex batches 
were made using an industrial level freeze dryer at Miles Pharamceutics 
in West Haven, Connecticut . The first batch yield (Ta ble XVI) was much 
poorer than expected (43% less). This process was carried out in an open 
tray freeze - drying system under a vacuum, thus, directly exposing the 
drying material to the applied vacuum. A large portion of the dried 
fluffy end product may have been inadvertently vacuumed away during the 
drying cycle. In order to increase the yield and decrease the percent 
loss, another batch was made with a minor modification to the open tray 
system (Fig . 30a). As shown in the Fig. 30b, a cover with an opening in 
the center was placed onto the open metal tray. In addition, a stainless 
steel screen (30 mesh) was used to cover the center opening (Fig. 30c). 
This equipment resulted in a reduction in direct exposure and prevented 
the loss of the drying material to the applied vacuum. The yield was 
significantly improved, limiting the loss to 27% (Table XVI) . 
The results of preliminary scale-up batches indicated that the 
preparation of the complex by freeze drying may be scaled-up to a 
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Table XVI 
Preliminary scale-up results of the phenytion beta-cyc lodextrin comp l ex. 
Batch No . 
2 
Batch size 
(liters ) 
10 
B 
Yield obtained 
(gms. ) 
113 
116 
Yie ld expected 
(gms ) 
198 
158 
% 
Loss 
43 
27 
Fig. 30: 
Key: 
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manufacturing level. In addition moisture content determinations of the 
complex and the drug content analysis (Table XVII) suggested that the 
method is also reproducible. It was felt that it may be possible to 
improve the yield by using finer screens to cover the center opening in 
Fig. 30b. A 60 mesh stainless steel screen over the center openi ng 
improved the yield from 73% to 90% (Table XVIII). Thus, it was clearly 
shown that the preparation of the phenytoin inclusion compound can be 
scaled-up to manufacturing level. The total length of time required to 
complete the ten liters batch was little less than two days (Appendix B, 
1), compared to four to five days to complete the lite r batch by using 
the laboratory freeze drier. In addition, in the laboratory freeze 
drier, it was not possible to determine the final end product temperature 
without breaking the vacuum system. However, as shown in Appendix B, 1, 
it was possible to determine quantitatively the final end product 
temperature. 
A phenobarbitone beta-cyclodextrin complex was also prepared using 
the same technique to improve the yield. It was possible to get a yield 
of more than 90%. The total length of time required to complete the ten 
liter batch was less than two days (Appendix B, 2). 
C. Preparation and evaluation of dosage forms 
1. Liquid dosage forms 
The compositions of two potential liquid formulations are given in 
Tables IV and V. These preparations were visually examined for clarity, 
( precipitation, crystal growth) change in color, odor, etc. After two 
weeks the formulation containing 10% glycerol, 40% sorbitol, and 20% 
syrup (Table V) showed slight precipitation and microbial growth. 
However, the formulation (Table IV) containing 40% glycerol, 20% sorbitol 
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Table XVII 
Some properties of the phenytion beta -cyclodextrin complex. 
Batch No 
2 
Batch size 
10 
8 
Moisture content 
6.50 
5.70 
% Drug content 
18 . 90 
18.30 
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Table XVIII 
Scale-up results of the phenytoin beta-cylcodextrin complex. 
Batch no. 
2 
3 
4 
Batch size 
( liters ) 
10 
8 
10 
10 
10 
Yield obtained 
(gms. ) 
113 
116 
160 
160 
180 
% Yield 
57 
73 
80 
80 
90 
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and 20% syrup did not show any precipitation or visual evidence of 
microbial growth after samples had been stored at ambient temperature up 
to four months. The probable reason for an increase in stability of the 
formulation is the higher concentration of glycerol, since glycerol 
itself acts as a preservative when it is present in higher concentrations 
(130). This formulation was compared with an official elixir (128 ) with 
respect to physical properties as well as one month's chemical stability 
data. The results are in Table XIX. The official formula contains 45% 
glycerol, 15% syrup and 15% alcohol. The alcohol content of the official 
preparation is required to keep the phenobarbitone in solution; however, 
the alcohol content in the official elixir may not be desirable, 
especially for pediatric use. For the phenobarbitone beta-cyclodextrin 
complex the addition of alcohol was not required. It has been reported 
(140,141) that in the case of elixir of phenobarbitone, propylene glycol, 
and a combination of poly- alcohols can be used as substitutes, and 
formulations using these substitutes have been proposed. Peterson and 
Hepponen (142) , developed a formula containing 35% of propylene glycol, 
20% syrup, and 0.4% of phenobarbitone with 0.1% flavoring oil . They did 
not report any chemical stability data, however, after three months 
physical stability was satisfacto ry. In order to aid in masking the 
bitter taste of phenobarbitone, and since propylene glycol does not add 
any sweetness as does the glycerol of the official formula , they 
increased the syrup content from the 15% of the official formula to 20%. 
However, their taste tests showed that the propylene glycol preparati ons 
were less acceptable than the official elixir. 
The formulation (Table IV) of the present study does not contain any 
propylene glycol, and the concentration of the glycerol is similar to 
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Table XIX 
One month chemical stability of solution prepared from the phenobarbitone 
beta-cyclodextrin complex, stored at room temperature. 
Product 
Fonnulation #1 (Table IV) 
Official elixir** 
* An average of three injections. 
% Label claim * 
94.80 
97 .60 
** Contains 45% glycerol, 15% syrup, 15% alcohol, and 0.4% 
phenobarbitone . 
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that of the official preparation. The taste was better than or equal to 
the official formulation. Furthermore, it is the op in ion of the author 
of this thesis that the complex could readily be used as a powder for 
reconstitution were any chemical stability problems to arise in the 
preparaticrn. 
A phenytoin suspension was prepared (Ta ble VI) from t he complex and 
its physical stability up to two years did not show changes in 
appearance, color, odor, etc. The results of the sedimentation study 
{Fig. 31), indicated that the sedimentation volume was slowly decreased 
during the first period of the week, then decreased gradua lly . However, 
even after six months, the sedimentation volume was approximately 60% of 
its original value. The redispersibility study showed that ten 
revolutions were required to restore the suspension to homogene ity. The 
blender rotation was 20 to 22 rpm. Hence, the suspension was easi ly 
redispersed within 30 seconds . In order to compare the ease of 
redispersability using the tech nique described in Experimental Section 
Ile, 2c, a light magnesium oxide suspension was introduced as a control. 
The percentage of solid content was the same as in the phenytoin 
suspension (Table VI) in the same suspending medium. However, due to 
formation of a concrete cake, it was not possible to redisperse the lig ht 
magnesium oxide suspension, even after five minutes. In contrast, the 
phenytoin beta-cyclodextrin complex suspension, which contained amorphous 
freeze dried material, formed a flocculated suspension. A floe, or 
floccule, by definition (143), is a loose aggregation of individual 
particles that are held together by comparatively weak 
particle-to-particle bonding forces; the sediment is loosely packed and 
has a scaffold - like structure. Particles do not bond tightly to each 
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Fig. 31: Sedimentation study of the suspension prepared from the 
phenytoin beta -cyclodextrin comp lex. 
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other, and a hard, concrete cake does not form. The sediment of our 
suspension was easy to redisperse, so as to form the original suspension. 
Generally, a typical suspension formula contains drug, suspending 
agent, suspending medium, flocculating agent, electrolytes, 
preservatives, etc . (144 ,145 ). But the formula selected in this study 
(Table VI ) contains only drug or suspensoid and suspending medium. It 
may also be noteworthy that a 50:50 mixtu re of water and glycerol as the 
suspending medium was chosen because of the poor solubility of phenytoin 
(138 ,146) plus the low solubility of beta -cyclodextrin in the suspending 
medium (147). The drug complex exhibits a minimum degree of solubility 
and thereby it is possible to achieve a maximum chemical stability. 
Hence, despite the high concentration of the solid content (10%) without 
any extra additives, the suspension possessed desirable qualities (144, 
145 and 148) such as ease of dispersion, high sediment volume, etc. 
These properties are indicative of a pharmaceutically elegant suspension. 
Furthermore, the suspension was stored in a freezer (a pp. -15°C) for a 
week. Since the freezing point of a 50:50 mixture of water and glycerol 
is -22.0°c (1 4g), the suspension did not freeze at all. This property is 
another of the desirable qualities of a pharmaceutically elegant 
suspension. Figures 32, 33 and 34 depict the morphology of the 
suspension stored at freezing station, refrigerator and at ambient 
conditions. As expected, it is evident from Fig. 32 that the suspension 
stored at freezing temperatures showed a slight increase in particle 
size, whereas Figs . . 33 and 34 showed little or no change in the particle 
size. It is the author's opinion that one week storage at freezing 
conditions is too severe, hence some change in particle size is to be 
expected. The photomicroscopic technique is one of the oldest and most 
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Fig . 32: Photomicrograph of the suspens ion stored dt - ts0 c ( 125x ) 
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Fig. 3'.3: Photomicrograph of the suspension stored at 5-s0 c 
( l 2Sx ). 
Fig. 34: Photomicrograph of the suspension stored at room 
tempera tu re. 
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useful for detecting changes in particle s ize and crystal form. Nash 
(145) also used a similar technique in the evaluation of physical 
stability of a suspension and also particle size measurement. However, 
he reported that particle size measurement using a photomicrograph gives 
an approximation but not an accurate value. Therefore Nash (145) 
suggested the use of a Coulter Counter, an electronic particle counter 
that measures the resistance caused by the presence of a particle in an 
electrolyte. Since it was not possible to use such an electronic 
particle counter, an estimation of the particle size was determined from 
Fig. 32 . An average of length of 25 particles was less than 25u. 
Another, distinct advantage is that, since this suspension contains 
freeze dried material, it is presented to the body in fine particles just 
like micronized particles ready for dissolution process immediately upon 
administration (150) . In addition, the suspension is less viscous and it 
was possible to pass 5ml of the suspension through a 22-gauge needle 
without a great difficulty. Hence, it may be possible to use the 
suspension for intramuscular administration. 
Anderson, F.M. ~ (59), reported that the bioavailability of 
femoxentine beta-cyclodextrin complex, formulated as a suspension, was 
found to be similar to that observed from a sugar-coated tablet of 
femoxetine salt. Their study would have been more meangingful if the 
bioavailability results had been compared with femoxetine suspension 
instead of its salt form. However, it was shown in their study that the 
salt form of femoxetine is equivalent to the inclusion complex of 
femoxetine. 
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2. So 1 id dosage forms 
As discussed in Section G (Technical aspects) of the Introduction 
portion of this thesis when a formulator is called on to develop a 
suitable dosage form for a new drug, he or she would likely first 
consider solid dosage forms, due to several reasons, mainly: 
a. Formulation and stability problems arise less frequently with solid 
dosage forms than with liquid pharmaceutical preparations (130). 
b. Solid dosage forms are preferred because of their ease of 
administration, dose uniformity, etc . 
When a formulator faces the problem of getting a sufficient quantity 
of active ingredients, an innovative modification of techniques to a 
semi-micro scale .- may well be needed. One of the most important 
considerations in solid dosage forms manufacture is a uniform flow rate 
of solid mixtures. Modern high speed tabletting or capsule-filling 
machines are capable of producing thousands of units per minute. Thus, 
an acceptable flow of solid mixtures is essential. Among the various 
methods used {151) to predict powder flow, various flowmeters have 
received considerable attention {135,136,152-155). These methods are 
useful if sufficient quantities of active ingredients are available. 
However, when a formulator faces the problem of getting a sufficient 
quantity of active ingredient, then the question becomes one of 
predicting the effect of formulation and processing variables on 
production scale quantities using a small quantity of material. In order 
to answer this question, miniturization of flow studies was undertaken 
and results are given in Table XX. 
It is evident in Table XX that good flow rate and a high linearity 
index were recorded through hoppers I and II as the mass was increased up 
Table XX - Comparisions of mass flow ratesa with linearity valuesb 
Ho er I.£ flo er I I~ Ho er III~ 
Dicalcium l ow rate Linearity Flow rate Linearity Flow rate linearity 
phosphate (Range) (Range) (Range) 
di hydrate, 
--------
--------------------- --------------------- ------------
100 49.7 (5.0) 19.0 
200 162.9 (27.6) 17.7 83.1 (6.80) 17.5 43.7 (1.9) 18.1 
300 177.8 (11.0) 18.2 85.2 (4.60) 19.5 40.4 (3.3) 16.7 
400 202.8 (10.0) 19.1 89.7 (5.50) 19.6 
600 206.7 (13.8) 19.5 95.7 (6.40) 19.7 
800 201. 5 ( 5. 30) 19.6 95.5 (4.60) 19.6 
1000 203.9 (8.00) 19.5 91.9 (1.70) 19.2 
ag/s (An average of three trial s ). b (r2 - 0.8) x 100; 1- Stainless stee l hopper from 
Stokes si ngle punch tablet press. 11 - Conical glass funnel . III_ Cylindrical glass funnel. 
w 
w 
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to 60% of the hopper capacity. However, the flow rate and linearity 
index were decreased through hopper III as the mass was increased from 30 
to 100% of the hopper capacity. Furthermore, effects of different levels 
of lubricant on flow rates were determined with a constant mass (200gm). 
The results are plotted in Fig. 35. It is evident that lower 
concentrations of magnesium stearate {0.3 and 0.6%) resulted in 
increasing flow rates from all three hoppers whereas, higher 
concentrations of lubricant levels (1.0 to 5.0%) resulted in a linear and 
faster decrease in flow rates with larger orifice diameter (hopper I) 
compared with the smaller orifice diameters {hoppers II and Ill). Since 
the three ho ppers are different in geometry and in size, variation in 
flow rate was to be expected. However, the results indicate that 
although different hoppers affect the quantitative nature of the results, 
the same general trends are apparent. Hence, this study indicates that 
it may be possible to use a recording powder flowmeter with small 
quantities of material in an attempt to predict the flow rate, effect of 
formulation and processing variables on production scale quantities. In 
addition, for routine quality control or in -process powder flow testing 
situations, using a small quantity of material is cost effective . This 
makes the recording powder flowmeter data useful in numerous quality 
control and in-process powder flow testing situations . The 
reproducibility and sensitivity of recording powder fl owmeter data for a 
number of systems are well documented in the the literature (152-155 ) . 
As also mentioned in Section G (Technical aspects ) of the 
Introduction to this thesis, cyclodextrins are expensive for large scale 
use. Table XX! shows some physical properties of beta-c ycl odextrin . It 
has reasonably good glow rate and compresssibility. However, as shown in 
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Table XX! 
Some physical properties of the beta - cyclodextrin 
Particle size distribution 
(in microns) 
0 - 74 
74 - 125 
125 - 149 
149 - 177 
177 - 250 
250 - 420 
Flow rate 
gm/sec 
3.2 
Bu 1 k density 
gm/cc 
0.54 
11.80 
25.70 
32 . 00 
15 . 00 
12 . 20 
3.10 
Tap density 
gm/cc 
0.68 
All the above values are an average of three trials. 
Compressibility 
% 
20.58 
137 
Table XX!!, the phenytoin beta-cyclodextrin complex prepared by various 
methods does not have either good flow or comp ressibili ty properties. 
Without a good flow it is very difficult if not impossible, to devel op 
solid dosage forms . The usual dose of phenytoin is lOOmg three times a 
day. Thus, based on the concentration of phenytoin (20%) in the complex, 
it is estimated that the total amount of the complex required would be 
SOOmg (equivalent to lOOmg phenytoin). Therefore, the complex would 
contribute a major portion of the t otal tablet weight. 
In order to enhance the flow properties especially of the freeze 
dried complex (poor flow, Table XX!!), different concentrations of the 
complex were mixed with a direct compression vehicle (Emcompress ) and 
flow rates evaluated. As the concentrati on of the complex was increased 
(Fig . 36), flow rate decreased drastically . An acceptable flow rate was 
found only when the conentration of complex was less than 5%. Thus, 
direct compression was not found to be feasible, since the final tablet 
weight would be more than a few grams. An attempt was made to prepare 
slugs, however, due to lack of compressibility and flowability of the 
complex, slugs could not be prepared. Thus wet granulation was the only 
method available for tabletting. Since freeze dried materials are 
generally highly soluble, it was thought that after addition of a 
granulating agent the material might agglomerate rap idly; however, no 
agglomeration problem was observed during the wet granulation process. 
It was then possible to develop a formula (Table VII) with an acceptable 
weight and size. It has been reported by Szejtli, J. (8) , who is one of 
the authorities in the field of cyclodextrin inclusion complexes that, 
"if the required dose amounts to several hundred milligrams, then 
especially with low molecular weight drugs, it would be necessary to 
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Table XX!! 
Some physical prperties of the phenytoin beta-cyclodextrin complex 
prepared by the various methods. 
omplex prepared by Fl ow Bulk 
Rate mg/s mg/cc 
Tap 
mg/cc 
Compressibility 
% 
-----------------------------------------------------------------------
!Freeze drying 33 65 167 61.08 
~pray drying 302 402 744 45.97 
Kneading 1836 480 727 33 .98 
~olvent evaporation 3270 512 717 28.60 
Emcompress* 4666 733 916 19.98 
* Used as a reference standard. 
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disperse several grams of cyclodextrin complex tablets. Thus no 
practical application of the complex seems to be likely." However, the 
phenytoin dose is lOOmg, ( by complexation with beta-cyclodextrin) and 
using the wet granulation method it was possible to make a tablet of 
625mg containing lOOmg phenytoin. It is in the opinion of the author of 
this thesis that if the drug content in the complex is less than 10%, and 
if the molecular weight of the drug is very low, practical application of 
cyclodextrin complexes for tabletting is highly unlikel y. 
Table XX!!! shows the particle size distribution, bulk properties, 
flow characteristic and compressibility of formulation prepared from the 
phenytoin beta-cyclodextrin complex. The complex was prepared by the 
freeze drying method and then wet granulated . By wet granulati on it was 
possible to achieve good flow rate and compressibility. Furthermore, 
tablets were compressed using an instrumented tablet press and Fig. 37 
depicts the results of compressibility. It is evident from Fig. 37 that 
there is almost a linear relationship between hardness and compression 
force, thus there was no problem during the compression. Tablets were 
examined for a variety of properties including weight variation, 
hardness, disintegration time, etc. Table XX!V lists all of these 
properties. All the examined properties meet the USP standards. Fig. 38 
shows the dissolution test data performed on weighed portions of the 
tablets; the figure shows that at 60 minutes more than 90% of the drug 
had dissolved. Fig. 39 depicts the dissolution test data performed in 
accordance with the USP monograph dissolution medium . In this plot (Fig. 
39) the dotted line represents the percent drug dissolved based on the 
equilibrium solubility of phenytoin (138). The dissolution results of 
three different products are shown in this plot. The three products are: 
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Table XX!! ! 
Some physical properties of granulation prepared fr om the phenyto in 
beta-cyclodextrin complex . 
Particle size distribution 
(in microns) 
0 - 74 
74 - 125 
125 - 149 
149 - 177 
177 250 
250 - 420 
!Flow rate 
gm/ s 
7.0 
Bulk density 
gm/c c 
0.5 1 
Tap density 
gm /cc 
0. 68 
~11 the above values are an average of three trials. 
24 . 25 
8. 75 
6. 24 
3.54 
7.75 
48 . 75 
Compressibility 
% 
25 
/ 
a 
6 
0 
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2 4 6 8 
COMPRESSI ON FORCE x 103Nrnro;<s 
Fig. 37: Comp ress io n study of th e formulation prepared from 
the freeze dried phenytoin be ta - cyclodextr i n comp l ex. 
Some physical properties of the tablets prepared from the phenytoin 
beta -cyclodextrin complex . 
Weight variation Hardness Thickness Friability 
(mg) (kg} (i nches) % 
335 7.5 
333 6. 5 
322 9.0 
335 8.5 
321 7. 0 
334 7.5 
334 8.0 
324 7.5 
324 6.5 
323 6.5 
325 7.0 
327 7.5 
325 8.0 
325 7.5 
323 7.0 
320 7.0 
322 6.5 
326 7.0 
325 7.0 
320 7.5 
Mean 326 7.33 
* (5 .0 } (0 .67 } 
*-Standard deviation 
0. 187 
0.188 
0. 188 
0.187 
0.190 
0.187 
0.187 
0.187 
0.187 
0.187 
0.188 
0.186 
0. 188 
0.188 
0.187 
0.191 
0.188 
0. 188 
0. 180 
0.190 
0.188 
(0.001} 
0.18 
Disintegration 
time (mintues) 
7.0 
6.5 
5.0 
5.5 
4.0 
6.0 
5.7 
( l. l ) 
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tablets prepared from the freeze dried beta -cyclodextrin complex; 
Infatabs from Parke-Davis; and phenytoin tablets prepared by Mr. S.R. 
Ghanta (gra duate student). It is evident that the phenytoin 
beta-cyclodextrin complex showed highest percent dissolved (more than 60% 
at 30 minutes). Because of th~ low aqueous solubility of phenytoin 
(138), dissolution was conducted with half tablets. However, as shown in 
the same plot (Fig. 39), there was no significant improvement in the 
dissolution rate in water. The tablets prepared from the freeze dried 
complex reached the equilibrium solubility within fifteen minutes; 
whereas, the other two phenytoin products did not reach the equilibrium 
solubility even after 60 minutes. Further, it was thought that, since 
the Infatabs are used as chewable tablets, they may erode very slowly and 
for this reason showed slowest dissolution rate. However, the 
instructions on the Infatabs bottle indicate that the tablets can be 
either chewed thoroughly before being swallowed or swallowed whole. 
Therefore these tablets were taken for comparison . Generally, chewable 
tablets are hard, they erode very slowly in the mouth, so that a slow 
dissolution rate is expected. However, when these tablets were crushed, 
passed through 60 mesh sieve and filled into capsules, then dissoltuion 
was compared (Fig. 40) with the similar preparation of the tablets 
prepared from the freeze dried complex. As shown in Fig. 40, the freeze 
dried complex showed significant improvement in the percent drug 
dissolved. Figure 41 shows the dissolution of phenytoin 
beta-cyclodextrin complex tablets after two years' storage at ambient 
temperatures, compared with a sodium phenytoin capsule (Zenith Labs). 
Tablets from the freeze dried complex reached the equilibrium solubility 
within 30 minutes. As shown in Fig. 41, the half tablets showed 
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significant improvement in the dissolution rate compared to sodium 
phenytoin capsules. 
Dissolution was also investigated in an acidic medium. The results 
are depicted in Fig . 42. In this plot, dissolution results of sodium 
phenytoin, freeze dried complex, physical mixture of phenytoin 
beta--cyclodextrin, and phenytoin powder alone are shown. As expected, 
the physical mixture and phenytoin did not improve dissolution . However, 
the dissolution rate of the complex and sodium phenytoin powder was by 
and large equal after a 30 minutes time period. Figure 43 shows the 
dissolution results of the freeze dried complex tablet (full and half) 
and sodium phenytoin capsule. As observed in Fig. 42, approximately 60% 
of the drug was dissolved from the complex within 60 minutes. The sodium 
phenytoin capsule showed a higher percent dissolution (apprx. 70%) within 
60 minutes. This increase in percent dissolved may be due to the effect 
of formulation and processing. However, the percent drug dissolved from 
the half tablets was higher at the 30 minute time period than sodium 
phenytoin capsule. These results indicated that even in the acidic 
medium the dissolution of the phenytoin beta-cyclodextrin complex was 
better or equal to the sodium phenytoin capsules. 
Since there was no signif icant difference between total percent drug 
dissolved in water and in an acidic medium, further dissolution work was 
carried out in water according to the USP (128) . Figure 44 shows the 
dissolution results of phenytoin beta-cyclodextrin complex prepared by 
the various methods. As indicated earlier the dotted line represents the 
equilibrium solubility of phenytoin in water at 37°C . In this plot the 
complex prepared by spray drying, kneading, etc, showed less than 40% 
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drug dissolved even at 60 minutes. Whereas, the complex prepared by the 
freeze drying method showed more than 60% dissolv ed at 60 minutes. 
This increase in percent dissolved is due to the amorphous nature of 
the freeze dried complex as seen earlier in X-ray analysis (Fig. 13c) and 
photomicrographs (27b ) . However as shown in Table XXV, there was no 
si gnificant difference i n disintegration time of phenytoin 
beta-cyclodextrin complex tablets prepared by the va r ious methods. 
Furthermore, it was thought that a decrease in partic le size of phenytoin 
may increase the dissolution rate similar to the freeze dried complex. 
Hence, phenytoin was freeze dried alone, compressed into tablets and 
dissolution was carried out. The results are shown in Fig. 44. As shown 
in Fig. 44, the freeze dried phenytoin did not improve t he dissolution 
rate However, when the freeze dried phenytoi n was mixed with fre eze 
dried beta-cyclodextrin, the tablets prepared from that mixture showed 
(Fig. 44 ) the similar resu lts as obta ined from the free ze dried complex. 
As shown in Fig. 44, there is a slight difference at 15 minutes time 
period; however, after that time period, the percent drug dissolved was 
by and large equal to the freeze dried complex. This unique phenomenon, 
may be due to the in situ complex formati on in the dissolution medium. 
It is the opinion of the author of this thesis that as far as ca n be 
ascertained, this unique phenomenon (i n situ complexation) is the first 
report of the interaction of beta-cyclodextrin wi th phenytoin. · 
Phenytoin is a high melting (293°C), weakly acidic (138 , 146 ) and 
poorl y water soluble drug (138). Because of these physicochemical 
properties, phenytoiri is subject to erratic and incomp lete 
bioava ilability (156-159). Phenytoin has been classified as a drug with 
"high risk potent ial " with respect to bioavailability problems (160 ,161). 
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Table XXV 
Disintegration time of the phenytoin beta -cyclodextrin complex tablets 
Prepared by the various methods. 
Mehtod of pre para ti on Disintegration time in minute~ 
(Standard deviation) 
Freeze drying 6.5 ( 1. 2) 
Spray drying 6. 0 (2 . 3) 
Kneading 7. 3 (3 .0) 
Solvent evaporation 7.8 ( 2. 5) 
l~ 
It has been reported that the rate of dissolution of phenytoin is 
influenced by particle size (162) , characteristics of excipients {163), 
manufacturing procedures and dosage form (164). 
Chakrabarti ~ (162) reported that significant differences in 
bioavailability were observed when phenytoin crystals of different 
particle size were administered. In their investigation 3 dogs were 
administered 390 _: lOmg capsules in a cross-over design with an interval 
of one week between two administrations. The radioimmunoassay method was 
used in the analysis of drug content . The largest area under the curve 
(AUC) and maximum concentration (Cmaxl were observed with smallest 
particle size (0-32u), followed by 75 and lOOu particle size 
respectively . Chakrabarti ~ {162) did not report the time required 
to reach maximum (Tmax l plasma level. The paired t-test was used to show 
the significant difference between the Cmax and the AUC among the 
treatments. They concluded that the AUC is inve rsely related to the 
particle size. In addition, their results were correlated with the 
faster dissolution of phenytoin of smaller particle size. It is the 
opinion of the author of this thesis that since the phenytoin 
beta-cyclodextrin complex prepared by the freeze drying method produced 
amorphous particles (less than 25u), and therefore a smaller dose would 
be enough to achieve the therapeutic range of plasma level (10- 20 ug/ml). 
Yakou ~ (163) , reported the effect of manufacturing procedures 
on the dissolution and human bioavailability of phenytoin. The 
dissolution characteristics of commercial phenytoin, freeze dried 
phenytoin, 20% simple blend of phenytoin with lactose and starch, and 20% 
solvent deposition of phenytoin powder were determined in pH 1.2 and 7.5 
test media. The results are summarized as follows: 
l~ 
a. The solvent deposition of phenytoin with PVP, showed the fastest 
dissolution rate (app. 15% in ten minutes). This increase in dissolution 
rate is probably due to improvement in the wetability of the phenytoin 
crystals as well as decrease in particle size. 
b. Based on the results of the in vitro studies, 20% phenytoin solvent 
deposition powder and the phenytoin crystals were selected for a 
bioavailability study in humans . A cross-over study was carried out in 
six healthy male volunteers, and 300mg of phenytoin was administered 
orally. The plasma samples were assayed for phenytoin by the method of 
enzymeimmunoassay. The urine samples were assayed for phenytoin by 
gas-liquid chromatography. 
c. The commercial crystals gave a very low plasma level and showed a 
significant difference was found at each time period. The coprecipitated 
powder gave 7.63-11.6 times larger AUC than the phenytoin crystals in 
individual volunteers and the mean was 8.97 times larger . The urinary 
excretion study also revealed a lower excretion rate of pheyntoin from 
the crystals. 
d. It was concluded from the above study that the phenytoin crystals 
(between 177-350u) gave significantly lower bioavailability than the 
coprecipitated powder due to poor dissolution characteristics of the 
fonnulation. However, the authors of this bioavailability study did not 
report the particle size range of the coprecipitated phenytoin powder. 
They simply reported that when the same batch of phenytoin crystals was 
processed by solvent deposition, the particle size might have reduced in 
the course of the manufacture to below the critical range ( less than 50u ) 
of crystal size distribution. Further, they concluded that a 
manufacturing method affects the bioavailability of phenytoin 
preparations substantially. 
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Sekikawa ~ (164) reported the dissolution behavior and 
absorption of phenytoin and phenytoin polyvinylpyrrolidone (PVP ) 
coprecipitate in five male subjects. The dissolution characteristics of 
phenytoin and coprecipitated phenytoin with PVP were determined in pH 1.2 
and 7. 5 test media. The results are summarized as follows: 
a . The dissolution rate of phenytoin coprecipitate was markedly 
increased (app. 31 . 50% in fifteen minutes) in the dissolution media. The 
concentrations of phenytoin following the dissolution of 1:3 or 1:5 
coprecipitates were 2.3 times as much as phenytoin solubility (25ug/ml ) 
in the test media . The dissolution rate of coprecipitate with PVP of 
lower molecular weight was greater (K- 15 K- 30 K-90) . 
b. Based on the results of the in vitro studies, a bioavailability study 
was conducted in five male subjects, and 250 mg of phenytoin was 
administered orally . A cross-over design was used . Urine was collected 
at hourly intervals for the first nine hours and at a convenient time 
intervals up to 120 hours after administration. The urine samples were 
assayed for the main metabolite (5-p-hydroxyphenyl-5-phenylhydantoin ) by 
a gas-liquid chromatography. Blood samples were not taken 
c. Following the administration of the coprecipitate, the maximum value 
of mean urinary excretion rate of the metabolite appeared in the 8-12 
hour period. Excretion rate of the coprecipitate was almost twice that 
of the phenytoin alone in the 8-12 hour time period. The intersubject 
variation of excretion rates were considerably smaller when the 
coprecipitate was administered. The recoveries of the metabolites 
excreted in urine for 120 hours following the administration of the 
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coprecipitate and phenytoin alone were 84 .3% and 54 . 7% respectively . 
Extent of bioavailability of phenytoin in phenytoin PVP-coprecipitate was 
1.54 times greater than that of phenytoin alone . Acco rding to the 
authors of the above study, higher excretion patterns may be considered 
to be a reflection of the in vitro dissolution behavior of each 
preparation. High dissoltuion rate and supersaturation of phenytoin f rom 
the coprecipitate resulted in the large improvement of the rate and 
extent of the bioavailability of poorly water - soluble phenytoin. 
Furthermore, Yakou et al (165) also reported the particle size dependency 
on dissolution rate and human bioavailability of phenytoin and phenytoin 
polyethylene glycol solid dispersions. The dissolution characteristics 
of phenytoin and phenytoin solid dispersion prepared at various ratios of 
polyethylene glycol 4000 were determined in pH 1.2. The results a-re 
summarized as follows: 
a. At lower ratios of phenytoin to polyethylene glycol (0 .5:10, and 
1:10) the bulk concentration reached a plateau of 43ug/ml (10 . 75%) in 
less than five minutes, while higher ratios (2:10, 3:10 and 4:10) gave 
rapid rises to 32ug/ml (8 . 0%) in five minutes with subsequent small 
increases. 
b. These results suggested that a rati o of less t han l to 10 is required 
to disperse phenytoin completely in polyethylene glycol. 
c. Further, the dissolution rate of different particle size suggested a 
critical particle size between 74- 149u for higher dissolution rate. 
d. Based on the results of the in vitro studies, a bioavailability study 
was conducted in five male subjects, and 300mg of phenytoin crystals 
(size 44-53um), 200mg of physical mixture with polyethylene glycol, and 
200mg of the solid dispersion powders were administered orally . A 
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three-way cross -over study was used. Blood samples were taken at 2, 4, 
6, 8, 12, 24, 32, 36, and 48 hour, and urine was also collected at the 
same i ntervals. The plasma samples were assayed for phenytoin by enzyme 
immunoassay and the levels of the intact phenytoin in urine were assayed 
by gas-liquid chromatography. The details of the assay methods are not 
reported. Phenytoin solid dispersion gave the highest plasma level 
(3.74ug/ml) in 5.6 hours, followed by the physical mixture and phenytoin 
alone. The physical mixture gave a plasmal level of (l.92ug/ml) in 6.8 
hours, and phenytoin gave a lowest plasma level of 0.75ug/ml in 5. 7 
hours. 
e. The areas under the plasma level curve were: phenytoin solid 
dispersion 73.86h . ug/ml, phenytoin physical mixture 50.26h.ug/ml, and 
phenytoin crystals 18.45h . ug/ml. There was a significant difference 
among the treatments as shown by Student 's-t-tes t. 
f . The urinary excretion rate from the solid dispersion of phenytoin in 
polyethylene glycol exceeded that from the physical mixture or the 
phenytoin crystal at any time. 
g. It was concluded from the above study that the phenytoin solid 
dispersion showed superior dissolution and bioavailability. These 
characteristics of the phenytoin solid dispersion should offer the 
clinical advantages of quick drug release and excellent bioavailability 
in phenytoin therapy. 
As previously mentioned in Section F, 6 (Bioavaila bility) of the 
Introduction to this thesis Tsurika ~ (95) studied the absorption of 
freeze dried phenytoin, phenytoin, and its beta-cyclodextrin complex in a 
group of four female beagle dogs. They reported that there was a 
two-fold increase in the area under the curve of the blood level. The 
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Student's-t-test showed a significant difference in the blood level 
curves . Jn addition, it was reported that an increase in bioavailability 
of phenytoin by means of beta - cyclodextrin complexation suggested the 
possibility of smaller doses and fewer side effects in phenytoin th erapy. 
The results of the in vitro dissolution studies of phenytoin 
obtained by Yakou ~ (163), Sekikawa et al (164), and Yakou et al 
(165) can be compared with the results obtained by the author of this 
thesis . These results are summarized in Table XXVJ. As shown in Tab le 
XXVI , it is clearly evident that phenytoin beta-cycl odextrin showed 
su perior in vitro dissolution results in all media . However, direct 
comparison may be questionable since dissolution results are a function 
of dissolution methodology, dissolution volume, agitation speed, etc. 
Despite these differences, it is in the opi ni on of the author of this 
thesis that the phenytoin beta-cyclodextrin complex dissolution rate is 
superior among all the preparations. Hence, it may be possible to use a 
smaller dose in in vivo studies with fewer side effects. Furthennore, 
the reported pheyntoin preparations such as solid dispersion, 
coprecipitation, etc. are prepared at a laboratory scale. The 
feasibility of fonnulation and incorporation in to a suitable dosage fonn 
are not explored. Physico -chemical properties are not fully tested, and 
hence direct practical application is skeptical. However, the scale of 
production of the phenytoin beta-cyclodextrin complex was increased from 
a laboratory scale to an industrial scale. Physico-chemical properties, 
feasibility of fonnulation, etc. are studied in this thesis. 
Anderson,~- (59), reported a preparation of an inclusion 
complex of femoxetine with beta-cyclodextrin by a precipitation method. 
The method of preparation was time consuming and labo r ious (one liter 
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Table XXV! 
Comparisons of the in vitro dissolution data of the tablets prepared 
from t he phenytoin beta - cyclodextrin complex with the literature data 
of other phenytoin tablets preparations. 
Phenytoin tablets preparation 
I* l. So 1 ve nt deposition 
** 2. Coprecipitaion with PVP 
'*** 3. Solid dispersion in 
Polyethylene glycol 
(0.5 : 10 . 0) 
4. Beta -cyclodextrin complex 
*-According to reference (163). 
**-According to reference (164) . 
***-According to reference (165) . 
NR- Not Reported 
% Drug dissolved in different media 
Time (minutes ) 
pH 1.2 pH 7.5 Water 
7.50 (10) 7.50 (10) NR 
31.50 ( 15) 25 . 23 ( 15) NR 
10 . 75 (5) NR NR 
pH 2. 2 pH 7.4 Water 
53 . 50 (15) 56 . 00 (15) 58.30 (15) 
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batch took one week to collect the precipitate and one day to dry in 
vacuum). The yield was onl y 87% . Scale-up evaluations, reproducibility, 
etc. were not reported. However, they had developed a suspension dosage 
fonn only on a small sacle (lOOml) from the complex. Physical properties 
of the suspension such as else of dispersion, sedimentation volume, 
freeze thaw study, etc., were not studied. Hence, the fonnulation 
feasibility and physical stability are to be investigated . 
Sea, et al. (88), studied the inclusion complex fonnations of 
spironolactone with three cyclodextrins (alpha, beta, and gamma). They 
obtained the solid complex by a precipitation method, it took seven days 
to precipitate the complex and then 48-hr to dry the complex at 6o 0c. 
The percent yield, scale-up, dosage fonn development, etc., were not 
reported . It is the opinion of the author of this thesis that the method 
is time consuming and also that the preparation of the solid complex of 
aqueous labile drugs can be a problem . However, the above authors did 
not report any stability problems . 
Iwaoka,~· (104), studied the abs orption of phenobarbitone from 
suppositories contaning beta-cyclodextrin . They dissolved the drug and 
beta-cyclodextrin in a molar ratio of 1:1 in hot water (temperature not 
reported), the solution was then filtered and left to crystall i ze (l ength 
of time not reported). In this study also details of the preparation of 
the complex, scale-up evaluation, etc., were not reported. However, 
after rectal administration of the suppository containing the 
beta-cyclodextrin complex to rabbits, the blood concentration of the drug 
was higher than that following administration of the phenobarbitone 
suppository. In the present thesis, the complex was prepared on a large 
scale; a batch of ten liters took less than two days, and the yield was 
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more than 90%. It is the opinion of the author of this thesis that the 
complex obtained by the freeze drying method was amorphous; hence it may 
be more easily uniformly dispersed in a melted suppository base than the 
crystalline complex obtained by Iwaoka~- (104). 
Tokumura, ~- (166), studied an inclusion complex of cinnarizine 
with beta-cyclodextrin in aqueous solution and in the solid state. They 
confirmed the inclusion formation by the solubility, powder X- ray 
diffractometry, differential scanning calorimetry and proton magnetic 
resonance spectroscopy methods. In order to prepare the complex, 
coprecipatation and neutralization methods were used . Scale -up 
evaluation, batch size, drug content in the complex, percent yield, etc., 
were not reported. Even though they reported that the dissolution rate 
of cinnarizine in the inclusion complex was 30 times larger than that of 
cinnarizine alone, they did not report on how one can conveniently 
incorporate the complex into a suitable dosage form. 
The literature is replete (87, 95, 101 - 103) with papers which report 
laboratory techniques of the preparation of inclusion complexes. It has 
been shown that dissolution and bioavailability of drugs improved by 
complexation with beta-cyclodextrin. However, how such inclusion 
complexes can be scaled- up from a laboratory scale to a pilot scale, 
formulation development, etc., have not been reported indetail. 
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IV Conclusions and suggestions for future work 
The following are believed to be the salient conclusions of this 
work as reported and discussed in the previous section. 
The data obtained in this thesis indicate that the beta -cyclodextrin 
interacts with ampicillin, phenobarbitone, and phenytoin. The mode of 
interaction was studied by a variety of methods, which include stability, 
solubility, X- ray diffractometry, differential scanning calorimetry, 
infrared and proton magnetic resonance spectroscopies, photomicrographs, 
etc. It was found that in the preparation of the complexes, the freeze 
drying method was the most feasible and reproducible from a laboratory 
scale to a pilot scale production. However, because of ampicillin 
instability under freezing conditions, it was not possible to obtain the 
inclusion compound in the solid powdered form. Phenobarbitone and 
phenytoin beta -cyclodextrin complexes were prepared using both a 
laboratory model freeze drier and an industrial model freeze drier. 
Modifications to the techniques in the freeze drying process allowed the 
yield to be improved to almost 90%. 
Properties of the complexes in solutions were evaluated by 
stability, solubility and proton magnetic resonance spectroscopy methods. 
In addition, to confirm the presence of the inclusion complex in the 
solid phase, X-ray diffractometry and differential scanning calorimetry 
techniques were found to be useful. Infrared spectra and 
photomicrographs were difficult to interpret in an unambiguous manner. 
However, these two methods are deemed to be useful to some extent; hence, 
they can not be ruled out in the evaluation of physico-chemical 
properties of the complexes. Liquid dosage forms were prepared from the 
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phenobarbitone and phenytoin beta-cyclodextrin complexes. A solution 
dosage form was prepared from the phenobarbitone beta-cyclodextrin 
complex . Unlike an official preparati on there was no need to use ethanol 
to keep the phenobarbitone in solution. Hence, this dosage form may hav e 
a considerable potential, mainly for pediatric use. Evaluation of the 
physical stability of the suspension prepared from the phenytoin 
beta-cyclodextrin complex were indicative of a pharmaceutica lly elegant 
suspension . In addition, another distinct advantage is that this 
suspension contains freeze dried material so it is presented to the body 
in fine particles and therefore ready for the dissolution process 
immediately upon administration. 
Despite the lack of flowability and compressibility of the phenytoin 
beta-cyclodextrin complex, it was possible to manufacture tablets of 
suitable size and weight. All the examined physical properties of the 
tablets were found to be within the USP standards. Dissolution studies 
of the tablets in different dissolution media indicated that the 
phenytoin beta-cyclodextrin had greatly improved dissolution compared to 
the uncomplexed drug. Due to in situ complexation of the physical 
mixture of the freeze dried phenytoin and beta-cyclodextrin, tablets 
prepared from the mixture showed a similar dissolution profile to that 
obtained from tablets prepared from the complex. However, a similar 
dissolution profile was not observed from the tablets prepared from the 
nonfreeze dried phenytoin and beta-cycl odextrin. Hence, it ma y be 
concluded that, when the substrate disperses at a molecular level, it 
comes in direct contact with the molecularly dispersed ligand and in situ 
complexation takes place in the dissolution medium. It appears that the 
rate limiting step to form in situ complexation is the solubility of a 
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substrate in the vicinity of the solution of a ligand. In order to 
increase the dissolution rate by in situ complexation, the following 
techniques may be useful: 
a. A physical mixture of a weakly acidic drug and cyclodextrins can be 
mixed with a GRAS (Generally Recognized As Safe) buffering agent to 
compress a tablet along with other tabletting ingredients. 
b. When such tablets disintegrate in the dissolution medium, the 
buffering agent will cause a rise in pH in the close proximity of 
disintegrated tablet. When there is an increase in pH, a weakly acidic 
drug will dissolve an·d may fonn an in situ complex with the molecularly 
dispersed cyclodextrins . This technique makes it possible to increase 
the dissolution rate of weakly acidic drugs. However, there are some 
assumptions to be made to make this technique work. Firstly, weak ly 
acidic drugs are stable in the presence of a buffering agent in the 
liquid as well as solid phase . Secondly, the amount of a buffering agent 
incorporated is sufficient to increase the pH in the dissolution medium 
so as to increase the solubility of weakly acidic drugs . Furthennore, 
due to an increase in the pH, acidic drugs will ionize (depending on pKa ) 
and the ionized species may not fonn a complex of suitable stability 
constant unlike unionized species . A similar technique may also be 
useful for basic drugs with appropriate buffering agents . 
In addition, the following suggestions can be given for future work. 
1. It would be interesting to investigate the interaction of an 
ampicillin with gamma-cyclodextrin, provided the cost is reasonable. 
2. Under controlled humidity and temperature facilities, micronization 
or co- grinding of ampicillin with cyclodextrins might be explored to 
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obtain the inclusion compound in solid powdered form, with subsequent 
evaluations of the physico-chemical properties of the complex. 
3. It is planned to conduct bioavailability studies of dosage forms 
prepared from the phenytoin beta-cyclodextrin complex in humans. 
However, because of today's myriad regulations, the dosage forms 
manufactured at URI (University of Rhode Island in the Department of 
Pharmaceutics facility cannot be used for testing in humans. The FDA 
(Food and Drug Administration ) requires brief statements that identify 
the place where the drug is manufactured and tested, an outline of the 
methods and facilities used in the manufacture, etc . , and these 
regulations requirements can not be met at URI. Hence, it is decided to 
manufacutre and conduct bioavailability studies of the dosage forms in 
appropriate (FDA approved) facilities, firstly in healthy humans (at 
least six) then in epileptic patients. 
4. At present, even though cyclodextrins are somewhat expensive for 
large scale use, because of their monumental potential in various fields, 
in the future cost of the cyclodextrins may well become more reasonable 
for pharmaceutical purposes . Hence, it would be interesting to study the 
interaction of alpha and gamma-cyclodextrins with other pharmaceuticals 
to improve their physico- chemical properties such as, stability, 
solubility, dissolution, etc. 
5. Furthermore, since the aqueous solubility of alpha and 
gamma-cyclodextrins is higher than for the beta - cyclodextrin, the 
complexes prepared from them may be useful for parenteral dosage forms. 
6. Although the literature reports the existence of delta, epsilon, and 
further homologues of cyclodext rins containing 9- 12 glycopyranose units, 
they are not available commercially in the pure form. However, even if 
l6i 
they become available in the future, complex formation will tend to 
diminish as the higher homologues of cyclodextrins increase in internal 
diameter. The probable reasons are as follows: The number of water 
molecules taken up by alpha, beta, and gamma cyclodextrins are 6, 11, and 
17, respectively. As the cyclodextrins' cavity is enlarged (with higher 
homologues), the properties of the water filling it will approach those 
of bulk water . Hence, the lowering of the energy of the entrapped water 
may account for the failure of the inclusion; alternatively, the 
inclusion "fit" may be too "loose". 
7. Recently, the chemically modified cyclodextrins have received 
considerable attention because their physico-chemical properties are 
different from the natural cyclodextrins. However, the practical 
application of modified cyclodextrins will have to await the results of 
exhaustive toxicological studies. 
Although a number of drug-cyclodextrin inclusion compounds are 
reported in the literature at the laboratory level, little attention 
appears to have been given to producing these products at the pil ot scale 
or manufacturing level. The results reported in this thesis clearly 
demonstrate that inclusion compounds not only can be produced at the 
pilot scale but also can be conveniently incorporated at a large scale 
into pharmaceutically acceptable dosage forms . 
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Appendix A, 1 
Precision of HPLC assa_y_method for amg_icill in 
Drug concentration 
Xl03M 
2.55 
2.52 
2.58 
No of injections 
3 
6 
* Relative Standard Deviation = S. O. x 100 
Mean 
Peak height 
25200 
25153 
24250 
19645 
20330 
20248 
24786 
24858 
24564 
24773 
24839 
24396 
192 
RSD( %)* 
2. 15 
1.86 
0. 74 
**A guideline for methods validation in New Drug Applications (NOA ) was 
followed in this analytical work. 
Appendix A, 1 (contd). 
Accurac_r_ of HPLC assay method for ampici 11 in 
Amount added 
(mg.) 
Amount found 
(mg.) 
193 
Recovery 
(%) 
~------ ---- - ------ --------------------------------------------- - --- - ---
1.003 1.012 100.90 
0.802 0. 772 96 . 17 
0.602 0.591 98.12 
0.401 0.410 102.30 
0.201 0.203 101. 20 
Mean 99.74 
Standard deviation = 2. 52 
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Appendix A, 2 
Precision of HPLC ass'!.l_method for phenobarbitone 
Drug concentration 
x 10-lM 
1. 72 
0.43 
No of injections 
6 
6 
Peak height 
20860 
20796 
RSD (%) 
21388 1.69 
20842 
21426 
21600 
5620 
5386 
5410 
5557 
5494 
5532 
1.60 
Appendix A, 2 (contd). 
Accuracy of HPLC assa..l'._rnethod for phenobarbitone 
Amou nt added 
(ucg) 
300 
300 
300 
100 
100 
100 
40 
40 
40 
Amount found 
(ucg) 
300.56 
300 . 20 
299.65 
98. 70 
99.00 
98.30 
38 . 88 
38 . 10 
38.40 
Mean = 
Standard deviation 
Recovery 
(:t) 
100 . 19 
100.06 
99.88 
98.70 
99.00 
98.30 
97 . 20 
95 . 25 
96.00 
98.29 
1. 77 
196 
0 .4 
0 . 3 
.; 
u 
c 
"' n 
... 
0 
VI 
. r.:i 0 . 2 
"' 
> 
::.J 
0.1 
I 
0 
L 
~ 
~ 
3 4 5 
Concentration x 10 M 
o-n2 = o. 909 
Slope = 4622 
lntcp. = 0.003 
6 
Fig . 47 Bee r' s plot for phenytoin us ing UV in an aqueous 111e <llum. \D 
..... 
1.0 
0.8 
0.6 
0.4 
0.2 
/ 
/ 
/ 
/ 
8 
/ 
/ 
/. 
/ 
/ 
/ 
16 
/ 
/ 
/. 
/ 
/ 
/ 
/ 
O - R2 = 0.994 
Slope = 19282 
lntcp. = 0.04 
0 -R2 = 0.997 
Slope = 19230 
Intcp. = 0.05 
24 32 40 
Concentration x 106M 
Fig . 48 Beer's plot for phenytoin using UV in pH 2 . 2 
198 
199 
1.0 
... 
/ 
/ 
/ 
/ 
0.8 / ~ 
/ 
.; / 
u / c 
0 - R2 "' 0.6 fl' 0.9 93 ..Cl s.. 
0 Slope 22300 Vl / 
..Cl 
"' 
/ Intcp. = 0.03 
:> / 
::::> 
0. 4 ..-: e -R2 = 0. 999 / 
/ Slope = 22800 
/ Intcp. = 0.04 
0. 2 / 
/ 
/ 
/ 
8 16 24 32 40 
Concentration x 106M 
Fig . 49 Beer's plo t fo r phenytoin using UV in pH 7.4 
200 
Appendix A, 3 
Pecision of spectophotometric assay method for phenytoin 
Drug concentration 
x 105M 
1.60 
3.17 
UV Absorbance 
0.206 
0.224 
0.218 
0.210 
0.229 
0.216 
0.763 
0.738 
0.747 
0.768 
0.750 
0.749 
RSD {%) 
3.93 
1. 47 
201 
Appendix A, 3 (contd) . 
Accuracy of spectrophotometric assay method for pher:I.toin 
Amount added 
(ucg) 
4 
4 
4 
8 
8 
8 
Amount found 
(ucg) 
3.78 
3.85 
3.90 
7.94 
7.80 
7.91 
Mean = 
Standard devivation 
Recovery 
('.t) 
94.50 
96.25 
97.50 
99.25 
97.50 
98.88 
97 . 31 
1. 75 
202 
Appendix A, 4 
Molar absorptivi~ (- ) of beta -cyclodextrin in pH 7.0 buffer 
Co ncentration of beta-cyclodextrin 
x103M 
1.25 
2.50 
5. 00 
10 . 00 
15 . 00 
at225nm 
7.15 
* Since the molar absorptivity of phenytoin (10191 ) was more than 
1000-fold compare to beta - cyclodextrin , hence it was felt that 
interference of beta-cyclodextrin may be insignificant . 
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Appendix B, 1 
B 16 24 32 40 48 
Time (Hours ) . 
Fig . 50 Freeze dry i ng cycle of phenytoi n beta -cylodextr i n 
compJex. 
Key : t:> - Product temperature, CJ - Heat applied, 
• - Condenser temperature. 
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Fig . 51 Freeze drying cycle of phenobarbitone beta-
cyclociextri n con;plex. 
Key: 6- Prociuct ter,1perature, a - Heat applied, 
• - Condenser temperature. 
